Protocol J2G- MC-JZJV (a)  
 
 An Open -Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of 
Dabigatran in Healthy Volunteers   [STUDY_ID_REMOVED]   Approval Date: 05- Mar-2021 
 
 
 
 
C O N FI D E N TI A L Pr ot oc ol  J 2 G -M C -J ZJ V (a) 
1C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s. It i s t h e p r o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli n i c al 
i n v e sti g ati o n of L Y 3 5 2 7 7 2 3 , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s 
s u b si di ari e s. 
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e nt i al 
i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e. Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y 
p u bli c r el e a s e. I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e 
r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s .
Pr ot oc ol Title: A n O pe n -La bel St u d y  t o I n vest i gate t he Effect of S el percat i ni b o n t he 
P har mac o ki net ics o f Da bi gatra n i n Healt h y V o l u nt eers 
Pr ot oc ol N u m ber: J 2 G -M C -J ZJ V 
A me n d me nt N u m ber: (a) 
C o m p o u n d :L Y 3 5 2 7 7 2 3 
St u d y P h ase: P hase 1 
S h ort Title: A D DI St u d y  of  Sel percat i ni b a n d Da bi gatra n i n Healt h y V o l u nt eers 
S p o ns or N a me: El i Lill y a n d C o m pa n y  o n be half of L o x o O nc o l o g y , I nc., a w h oll y  o w ne d 
s u bsi diar y  of  Eli  Lill y a n d C o m pa n y 
Le g al Re gistere d A d dress: I n di a na p olis, I n dia na 4 6 2 8 5 U S A 
Re g ul at or y A ge nc y I de ntifier N u m ber(s) :
I N D: 1 3 3 1 9 3 
A p pr o v al D ate: Pr ot oc ol El e ctr o ni call y Si g ne d a n d A p pr o ve d b y Lill y o n date pr o vi de d bel o w. 
A p pr o v al D at e: 0 5- M ar- 2 0 2 1 G M T 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
3Table of Contents
1. Protocol Summary ...................................................................................................... 6
1.1. Synopsis ....................................................................................................................... 6
1.2. Schema ......................................................................................................................... 9
1.3. Schedule of Act ivities (SoA) ...................................................................................... 10
2. Introduction .............................................................................................................. 14
2.1. Study  Rati onale .......................................................................................................... 14
2.2. Backgro und................................................................................................................ 14
2.3. Benefit/Risk Assessment ............................................................................................ 15
3. Objectives and Endpoints ......................................................................................... 16
4. Study Design ............................................................................................................. 17
4.1. Overall Design ............................................................................................................ 17
4.2. Scientific Rationale for Study  Desi gn......................................................................... 17
4.3. Justification for Dose .................................................................................................. 17
4.4. End of Study  Definit ion.............................................................................................. 18
5. Study Population ...................................................................................................... 19
5.1. Inclusio n Cri teria........................................................................................................ 19
5.2. Exclusio n Cri teria....................................................................................................... 20
5.3. Lifes tyle Considerat ions............................................................................................. 23
5.3.1. Meals and Dietary  Restri ctions................................................................................... 23
5.3.2. Caffeine, Alcoho l, and Tobacco .................................................................................. 23
5.3.3. Activity...................................................................................................................... 23
5.4. Screen Failures ........................................................................................................... 23
6. Study Intervention .................................................................................................... 24
6.1. Study  Intervent ions Administered ............................................................................... 24
6.1.1. Administrati on Details ................................................................................................ 24
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 24
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 25
6.4. Study  Intervent ion Compliance ................................................................................... 25
6.5. Concomitant Therapy .................................................................................................25
6.6. Dose Modificat ion...................................................................................................... 26
6.7. Intervention after the End of the Study ........................................................................ 26
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 27
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 27
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 28
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 28
7.3. Lost to Follow -
up....................................................................................................... 29
8. Study Assessments and Procedures ......................................................................... 30
8.1. Efficacy Assessments .................................................................................................30
8.2. Safety Assessments .................................................................................................... 30
8.2.1. Physical Examinat ions................................................................................................ 30
8.2.2. Vital Signs.................................................................................................................. 30
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
48.2.3. Electrocardiograms ..................................................................................................... 31
8.2.4. Clinical Safety  Laboratory  Assessments ..................................................................... 31
8.2.5. Safety Moni toring ....................................................................................................... 32
8.3. Adverse Events and Serious Adverse Events .............................................................. 34
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 34
8.3.2. Method of Detecting AEs and SAEs ........................................................................... 34
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 35
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 35
8.3.5. Pregnancy ................................................................................................................... 35
8.3.6. Product Complaint s.................................................................................................... 36
8.4. Treatment of Overdose ............................................................................................... 37
8.5. Pharmacokinet ics........................................................................................................ 37
8.5.1. Bioanalysis ................................................................................................................. 37
8.6. Pharmacodynamics ..................................................................................................... 37
8.7. Genet ics..................................................................................................................... 37
8.8. Biomarkers ................................................................................................................. 38
8.9. Immunogenicit y Assessments ..................................................................................... 38
8.10. Health Economics ....................................................................................................... 38
9. Statistical Considerations ......................................................................................... 39
9.1. Statistical Hypotheses .................................................................................................39
9.2. Sample Si ze Determinat ion......................................................................................... 39
9.3. Popul ations for Analyses ............................................................................................ 39
9.3.1. Study  Parti cipant Disposit ion...................................................................................... 39
9.3.2. Study  Parti cipant Characterist ics................................................................................. 39
9.3.3. Treatment Compliance ................................................................................................ 39
9.4. Statistical Analyses ..................................................................................................... 40
9.4.1. Safety Analyses .......................................................................................................... 40
9.4.2. Pharmacokinet ic Analyses .......................................................................................... 40
9.4.3. Pharmacodynamic Analyses ....................................................................................... 41
9.4.4. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 41
9.5. Interim Analyses ......................................................................................................... 41
9.6. Data Monitoring Committee ....................................................................................... 41
10. Supporting Documentation and Operational Considerations ................................ 42
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 42
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 42
10.1.2. Financial Disclo sure................................................................................................... 42
10.1.3. Inform ed Consent Process .......................................................................................... 43
10.1.4. Data Protection ........................................................................................................... 43
10.1.5. Disseminat ion of Clinical Study  Data ......................................................................... 43
10.1.6. Data Qualit y Assurance .............................................................................................. 44
10.1.7. Source Documents ................................ ...................................................................... 46
10.1.8. Study  and Si te Start and Cl osure ................................................................................. 46
10.1.9. Publicat ion Policy ....................................................................................................... 46
10.1.10. Long -Term  Sample Retent ion..................................................................................... 47
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
510.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 48
10.2.1. Blood Sam pling Summary .......................................................................................... 50
10.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 51
10.3.1. Definit ion of AE......................................................................................................... 51
10.3.2. Definit ion of SAE ....................................................................................................... 52
10.3.3. Recording and Fo llow-up of  AE and/or SAE .............................................................. 53
10.3.4. Reporting of SAEs ...................................................................................................... 55
10.4. Appendix 4: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 56
10.5. Appendix 5: Genetics .................................................................................................59
10.6. Appendix 6: Liver Safet y: Requi red Act ions and Follow -up 
Assessments ............................................................................................................... 60
10.7. Appendix 7: Abbreviat ions......................................................................................... 65
10.8. Appendix 8: Protocol Amendment History .................................................................68
11. References ................................................................................................................. 69
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
61. Protocol Summary
1.1. Synopsis
Protocol Title: An Open -Label Study  to Invest igate the Effect of Selpercat inibon the 
Pharmacokinet ics of Dabigatran in Healt hy Vo lunteers
Short Title: A DDI Study  of Selpercat iniband Dabigatran in Healt hy Vo lunteers
Rationale :
The P -gp is a m embrane -bound, efflux transporter located in the small intest ine, colon, and liver 
(among other tissues), serving to limit the absorption of drugs from the gastrointestinal tract and 
to increase biliary secret ion of drugs and their metabo lites. Certain substrates of P -gp have been 
shown to have clinically significant drug interactions when adm inistered with inhibitors of P -gp 
(International Transporter Consortium et al. 2010). 
This study  aims to eval uate the safety , tolerabili ty, and PK of dabigatran in the presence of 
selpercat inib. Dabigatran is a sensit ive substrate of the efflux transporte r P-gp (FDA Clinical 
DDI Guidance, 2020). Selpercatinib is an inhibitor of P -gp in vitro; an effect of selpercatinib on 
P-gp in the intestine cannot be ruled out. Based on the pH -dependent solubilit y of selpercatinib, 
the potenti al gut concentrati ons of se lpercat inib are higher under fed condit ions com pared to 
under fasted condit ions. Therefore, this study  is desi gned to address the potential effect of 
selpercat inib on P -gp in the intestine under fed condit ions to accoun t for the worst scenario of 
selpercat inib inhibit ion.
Objectives and Endpoint s:
Object ives Endpoints
Primary
To evaluate the effect of selpercat inib 
on P- gp activit y in healthy 
participantsCmaxand AUC (0-∞)of dabigatran to 
assess P-gp activit y
Secondary
To evaluate the safet y and tolerability
of dabigatran in co mbinat ion with 
selpercat inib in healthy participants
To evaluate the pharmacokinet ics of 
selpercat inibSummary  of the number of 
treatm ent-emergent adverse events and 
serious adverse events
Cmax, AUC(0 -∞), and tmaxof 
selperc atinib
Overall Design :
Screening
All participants will be screened within 28 days prior to enrollment (Day  1). 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
7Treatment and Assessment Period
Eligible participants will take part in 1 treatment period. Participants will be admitted to the CRU 
on Day  -1 and rem ain resident in the CRU unt il discharge on Day 11. All participants will 
receive a single dose of 150 mg dabigatran on Day 1 and a single dose of 150 mg dabigatran 
coadministered with a single dose of 160 mg selpercatinib on Day 8. There will be a washout 
period of  7days between dosing on Days 1 and 8.
Pharmacokinet ic blood sampling and safet y assessments, including vital signs measurements , 
physical examinat ions, clinical laboratory  tests, ECGs, and AE recording, will be performed 
according to the SoA (Section 1.3).
Follow -up
Parti cipants will return to the CRU for a safet y follow-up visit within 14 to17 day s after the final 
dose.
Disclosure Statement : This is a Phase 1, fixed -sequence , open -label study  in healthy 
participants.
Number of Participant s:
Up to 40participants will be enro lled to ensure that at least 30evaluable participants complete.
Intervention Groups and Duration :
This is a single -group study ,consist ing of single oral doses of dabigatran ( Day 1) and single oral 
doses of dabigatran andselpercatinib ( Day 8).
Dabigatran/Selpercatinib
Day 1 Day 8
Dabigatran (150 mg)Dabigatran (150 mg) + 
Selpercat inib (160 mg)
A single oral dose of dabigatran etexilate 150 m g will  be administered in the m orning of Day  1. 
On the m orning of Day  8, a single dose of dabigatran etexilate 150 mg and selpercat inib 160 mg 
will be administered orally wit h approximately 240 mL of room temperature water while in a 
sitting posi tion. Parti cipants will not be allowed to lie supine for 2 hours after dosing, unless 
clinically indicated or for study  procedures.
During theconfinement period, participants will consume only food and beverages that are 
provi ded to them  by the CRU staff. Sta ndard meals (e.g., breakfast, lunch, dinner, and snack) 
will be provided to the participants while resident at the CRU.
Dabigatran and selpercat inibwill be administered with food using a standardized unit meal.
The m acronutri ent com position of  the standar dized meals for dabigatran and selpercat inib 
administration should be targeted to provide approximately 50% of  the cal ories from 
carbohydrates, 15% protein, and 35% fat .The total calories for the standardized meal to be 
consumed with each dose is expected to be approximately  685 cal ories.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
8Parti cipants will consume thestandard ized meal 30 minutes prior to administration of study  
intervent ionand partici pants shoul d eat t his meal in 30 minutes or less. No addi tional food 
shoul d be allo wed for at l east 4 hours after drug administration.
Data Monitoring Committee : No
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
91.2. Schema
Study 
Day
-28
 -1
 1
 8
Dabigatran 150 mg
Dabigatran 150 mg + Selpercatinib 160 mg
Screening
 Wash -out Period
22 to 25
Follow Up
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
101.3. Schedule of Activities (SoA)
Screening DaysFollow -
Up/EDComments
Procedure -28 to -2 
days prior 
to Day 1-1 1 2 3 4 567 8 9 10 11Within 
14 to 17 
days 
after 
final 
dose
Informed consent X
Inclusion and exclusion 
criteriaX
Demography X
Participant Admission to 
CRUX
Participant Discharge 
from CRUX
Outpatient visit X X
Medical history  (includes 
substance usage [and 
family  history  of 
premature cardiovascular
disease])X
Past and current medical 
conditio nsX
Physical examination X X X XFull physical 
examination 
(including height and 
weight) to be 
performed at 
screening. 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
11Screening DaysFollow -
Up/EDComments
Procedure -28 to -2 
days prior 
to Day 1-1 1 2 3 4 567 8 9 10 11Within 
14 to 17 
days 
after 
final 
dose
Symptom -driven 
physical 
examinations tobe 
performed at all other 
timepoints.
Serum or urine 
pregnancy test (w omen 
of childbearing potential 
only)X X X XSerum pregnancy test 
will be performed at 
screening. Urine 
pregnancy test will 
be performed at 
every admission to 
theCRU and at 
poststudy, if 
applicable.
Human 
immunodeficiency virus, 
hepatitis B and C screenX
Urine or breath ethanol 
test X X
Urine drug screen X X
12-lead ECG XP, 
2hXP, 
2hXSingle ECGs are 
required.
Vital signs (supine) X XP, 
1, 
2h24h XP, 
1, 
2h24h XTime points may be 
added, if warranted 
and agreed upon 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
12Screening DaysFollow -
Up/EDComments
Procedure -28 to -2 
days prior 
to Day 1-1 1 2 3 4 567 8 9 10 11Within 
14 to 17 
days 
after 
final 
dose
between Lilly and the 
investigator.
Clinical laboratory  tests
(include liver 
chemistries)X X 24h X 24h XSee Appendi x 10.2 , 
Clinical Laboratory 
Tests, for details.
Genetic sample X
PK samples -Dabigatran 
(plasma)P, 
0.5, 
1, 
2, 
3, 
4, 
6, 
8, 
10, 
12h24, 
36h48h 72hP, 
0.5, 
1, 
2, 
3, 
4, 
6, 
8, 
10, 
12h 24, 
36h48h 72h
PK samples -
Selpercatinib (plasma)P, 
0.5, 
1, 
1.5, 
2, 
3, 
4, 
6, 
8, 
10, 
12h24, 
36h48h 72h
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
13Screening DaysFollow -
Up/EDComments
Procedure -28 to -2 
days prior 
to Day 1-1 1 2 3 4 567 8 9 10 11Within 
14 to 17 
days 
after 
final 
dose
Selpercatinib
administrationX
Dabigatran 
administrationX X
Adverse event /Serious 
adverse event reviewX X =========================================  X
Concomitant medication 
reviewX X =========================================  X
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
142. Introduction
Selpercat inib has been developed by Loxo Onco logy, Inc and acquired by  Eli Lilly and 
Com pany (Lilly ), and has been approved by  the FDA for the treatm ent of advanced or metastatic 
RET -mutant MTC , and advanced or metastatic RET fusio n-positive thy roid cancer , inadults and 
children ≥12years; and for the acute treatment of metastati c RET fusio n-positive NSCLC in 
adults.Full details of the preclinical and clinical safet y and tol erabilit y data are contained in the 
IB.
2.1. Study Rationale
The P -gp is amembrane -bound, efflux transporter located in the small intest ine, colon, and liver 
(among other tissues), serving to limit the absorption of drugs from the gastrointestinal tract and 
to increase biliary secret ion of drugs and their metabo lites. Certain substrates of P -gp have been 
shown to have clinically significant drug interactions when administered with inhibitors of P -gp 
(International Transporter Consortium et al. 2010).
This study  aims to eval uate the safety , tolerabili ty, and PK of dabigatran in the presence of 
selpercat inib. Dabigatran is a sensit ive substrate of the efflux transporter P -gp (FDA Clinical 
DDI Guidance, 2020). Selpercatinib is an inhibitor of P -gp in vitro ;an effect of selpercatinib on 
P
-gp in the intestine cannot be ruled out. Based on the pH -dependent solubilit y of selpercatinib,
the potenti al gut concentrations of selpercat inib are high erunder fed condit ionscompared to 
under fasted condit ions.Therefore, t hisstudy  is designed to address the potential effect of 
selpercat inib on P -gp in the intestine under fed condit ionsto accoun t for the worst scenario of 
selpercat inib inhibit ion
.
2.2. Background
Selpercat inib ( LY3527723) is a highly potent and specific small -molecule inhibitor of the RET
kinase, wi th minimal inhibit ion of other kinase and nonkinase targets.  
Selpercat inib doses have been evaluated in healt hy participants or patients with advanced or 
metastati c RET -mutantMTC , advanced or metastatic RET fusio n-positive thy roid cancer, and 
metastati c RET fusio n-positive NSCLC across Phase 1, 2, and 3 clinical studies. Across these 
studi es, single oral doses of selpercat inib were administered over a range of 20to 720mg. 
Multiple oral doses of 160mg/dayselpercat inib were administered orally  twice daily for 10days
in healthy volunteers.The most frequent ly reported (≥15% of participants regardless of 
attribution to study  drug) AEs in the ongoing first -in-human dose finding study  were dry  mouth, 
diarrhea, hypertensio n, AST/ALT increased, fatigue, const ipation, edema peripheral, nausea, 
headache, blood creatinine increased, abdo minal pain, rash, ECG QT prol onged, cough, 
vomiting,anddyspnea .
Themediantmaxof selpercat inib is 2hours and is slowly eliminated wi th a mean t 1/2of 
approximately  32hours in healt hy vo lunteers. More d etailed information about the PKand 
absorpti on, di stribut ion, metabo lism, and excret ionproperties o f selpercat inibmay be found in 
the IB.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
15Dabigatran etexilate, a compet itive, direct thrombin inhibitor, is a P -gp substrate. Following 
absorpti on, dabigatran etexilate is hydrolyzed to form dabigatran, the active moiet y. Dabi gatran 
concentrations reach t maxwithin 2 hours of administration, and then concentrations decline in a 
biphasic manner, with a terminal t 1/2of 12 to 17 hours. Dabigatran is primarily  eliminated 
through renal excretion and does not appear to be a substrate for renal transporters based o n the 
reported renal clearance of 89 mL/min (Stangier 2008). Dabigatran itself is not a substrate for the 
cytochrom e P450 family of metabo lizing enzyme nor a substrate for P -gp, meaning that changes 
in dabigatran exposure fo llowing administrati on of a P-gp inhibitor would be ant icipated to only 
reflect the activit y of the inhibi tion of  dabigatran etexilate transport at the intestinal wall 
(Stangier 2008). Previous studies have investigated the effect of P -gp inhibitors on dabigatran 
PK. Dabigatran AUC incre ased by  58% and 5 3% when coadministered with amiodarone and 
quinidine , respectively (Pradaxa®Prescribing Informat ion). Ketoconazole, a strong P -gp 
inhibi tor, increased dabigatran AUC and Cmaxvalues by 138% and 135%, respectively, after a 
single dose of 4 00 m g, and 153% and 149%, respectively, after mult iple daily 400
-mg doses 
(Pradaxa®Prescribing Information).
2.3. Benefit/Risk Assessment
There i s no antici pated therapeuti c benefi t for the parti cipants in thi s study . However , 
participants m ay benefi t from thescreening procedures (through detection of unknown healt h 
issues) even if they  receive no therapeutic benefit from the study .
The dose of selpercat inib to be given in this study is 160 mg , as it is the highest approved dose .
The safet y profile of selpercat inib is very well tolerated in healt hy vo lunteersandisclinically  
manageable, with the low rates of study  drug di scont inuat ion due to AEs. As outlined in the IB, 
the most comm on toxicities associ ated wi th selpercatinib are monitorable and reversible and 
include dry  mouth, diarrhea, hypertension, fat igue,  consti pation, AST/ALT elevat ion, headache, 
nausea, edem a peripheral , abdo minal pain, rash, electrocardiogram QT prolonged, cough, 
vomiting, dy spnea and increased blood creat inine. Events of special interest include 
hypersensit ivity, liver -function test abnormalit ies, throm bocy topenia, and hypertensio n.
The dabigatran dose to be administered in this study (150 mg) is within the therapeutic range 
(see Se ction 4.3), and has previously been administered to healthy vo lunteers wi th no tolerabili ty 
concerns in other D DI studies ( e.g., I8D-MC-AZEE; [STUDY_ID_REMOVED]) .
More detailed info rmation about the known and expected benefits and risks and reasonably 
expected AEs of selpercatinib may be found in the IB.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
163. Objectives and Endpoints
Object ives Endpoints
Primary
To evaluate the effect of selpercat inib 
on P- gp activit y in healthy participantsCmaxand AUC (0-∞)of dabigatran to 
assess P
-gp activit y
Secondary
To evaluate the safet y and tolerability
of dabigatran in co mbinat ion with 
selpercat inib in healthy participants
To evaluate the pharmacokinet ics of 
selpercat inibSummary  of the number of 
treatm ent-emergent adverse events 
and serious adverse events
Cmax, AUC(0 -∞), and tmaxof 
selpercat inib
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
174. Study Design
4.1. Overall Design
This is a Phase 1, fixed -sequence, open -label study in healt hy participants that will study  
dabigatran P -gpDDI with selpercat inib. The ant icipated study  durati on for each individual 
participant is approximately 8 weeks.
Screening
All participants will be screened within 28 days prior to enrollment (Day  1). 
Treatment and Assessment Period
Eligible participants will take part in 1treatment period. Participants will be admitted to the CRU 
on Day  -1 and rem ain resident in the CRU unt il discharge on Day 11.All participants will 
receive a single dose of 150 mg dabigatran on Day 1 and a single dose of 150 mg dabigatran 
coadministered with a single dose of 160 mg selpercatinib on Day 8. There will be a washout 
period of  
7days between dosing on Days 1 and 8.
Pharmacokinet ic blood sam pling and safet y assessments, including vital sign smeasurements, 
physical examinat ions, clinical laboratory  tests, ECGs, and AE recording ,will be performed 
according to the SoA (Section 1.3).
Follow -up
Parti cipants will return to the CRU for a safet y follow-up visit within 14 to17 day s after the final  
dose.
4.2. Scientific Rationale for Study Design
A single 160- mg dose of selpercatinib was selected as it is the highest approved dose for 
selpercat inibuse in adul ts.
In order to allow each participant to act as hi s/her own control for safet y and PK co mpar isons , a 
fixed sequence design has been selected. This study  will also be open -label as the study  primary  
endpo int PK m easures are obj ective rather than subject ive.
Based on the t1/2of dabigatran , a period of 7days between dabigatran doses is considered 
sufficient time for the study  drug to washout.
Conducting the study  in healt hy participants mitigates the potential confounding effects of the
disease state and concomitant medications in partici pants wi thmetastatic RET fusio n-positive 
NSCLC ,advanced or m etastati c RET -mutant MTC , or advanced or metastatic RET 
fusion-positive thy roid cancer . A populat ion of healt hy participants isfrequent ly used in the 
assessment of the PKof both sm all and large m olecules.
4.3. Justification for Dose
Dabigatran etexilate is current ly approved in the United States to reduce the risk of stroke and 
systemic embo lism in patients with nonvalvular atrial fibrillat ion, for the treatment of deep 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
18venous thrombosis and pulmo nary embo lism, and to reduce the risk of recurrence of deep venous 
thrombosis and pulmo nary embolism(Pradaxa Prescribing Information). The recommended dose 
for dabigatran etexilate is 150 mg twi ce daily for patients with creatinine clearance >30 mL/min 
(Praxada Prescribing Informat ion). Single oral doses of 10 t o 400 mg dabigatran etexilate have 
been administered to healthy participants and were well tolerated (Stangier et al. 200 8).There is 
a  possibilit y of an interact ion of dabigatran etexilate with selpercat inib and the dose sel ected 
allows for this possibi lity. 
The selected 150 mgdose for this stud y shoul d provi de adequate 
plasma dabigatran concentrations to address the study  object ives wit h minimal risk for AEs 
(Härtter et al. 2013).
The dose level o f 160mg is the highest approved dose for selpercatinib .
The doses will be administered at approximately the same t ime on Day 1 and Day 8 . The actual  
time of dose administrations will be recorded in the participant’s electronic CRF .
4.4. End of Study Definition
A participant i s considered to have co mpleted the study  if he/she has co mpleted all requi red 
phases of the study  including the last vi sitor the last scheduled procedure shown in the SoA.
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study  or 
last scheduled procedure shown in the SoA for the last participant in the study globally.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
195. Study Population
Eligibilit y of parti cipants for enrollment in the study  will be based on the results of screening 
medical history , physical examinat ion, vital signs, clinical laboratory  tests, and ECG.
The inclusio n and exclusio n criteria used to determine eligibilit y shoul d be applied at screening 
only, and not continuously throughout the study .Clinical laboratory assessments and v ital signs 
may be repeated from screening t hrough Day -1 at the discret ion of the invest igator in order to 
confirm eligibilit y.
Screening may occur up to 28 day s prior to enrollment. Parti cipants who are not enrolled within 
28 day s of screening may  undergo an addit ional medi cal assessment and/or clinical 
measurements to confirm their eligibilit y. In such instances, the following screening tests and 
procedures should be repeated : clinical laboratory  assessments and vital signs.
Prospective approval  of protoc ol deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1.Parti cipant m ustbe 18to 65years of age ,inclusive, at the time of signing the ICF.
Type of Participant
2.Parti cipants who are overtly healt hy as determined by  medical evaluat ion including 
medical history , physical examinat ion, and vital signs .
3.Parti cipants who have clinical laboratory  test results wi thin the norm al reference range 
for the popul ation or invest igative site, or results wit h acceptable deviat ions that are 
judged to be not clinically significant by  the investigator.
4.Parti cipants who have venous access suf ficient to allow for blood sampling as per the 
protocol .
Weight
5.Have a body  mass index wi thin the range 19.0 to35.0 kg/m2(inclusive).
Sex
6.Male or f emale
Contraceptive use by men or women should be consistent with local regulat ions regarding 
the methods of contracepti on for those parti cipat ing in clinical studies.
Male parti cipants:
are not required to adhere to con tracepti ve requi rements
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
20Female participants:
Female participants of childbearing potential (see Appendix 10.4) who are abst inent 
(if this is com plete abstinence, as their preferred and usual lifestyle) or in a same sex 
relationship (as part of their preferred and usual lifest yle) must agree to either remain 
abstinent or stay  in a same sex relat ionship wi thout sex ual relationships wi th males. 
Periodic abst inence (e.g., calendar, ovulat ion, symptothermal, post -ovulation 
methods), declaration of abst inence just for the duration of a study , and wi thdrawal 
are not acceptable methods of contraception.
Female participant sof childbearing potential, who are not abstinent as described 
above, must agree to use a highly  effect ive method of contraception (that is, one with 
less than 1% failure rate) such as co mbination or oral contraceptives, 
implanted/injected contraceptives, intrauteri ne devices, or sterile partner until 
30days after the l ast dose of study  medicati on. 
o Female participants not of childbearing potential are not required to use 
contraception. This includes females who are:
Infert ile due to surgical sterilizatio n (hysterectomy, bilateral 
oophorectomy , bilateral  salpingectomy , or tubal  ligation) or congenital 
anomaly (for example, Müllerian agenesis)
Postmenopausal  asdefined in Appendix 10.4.
Informed Consent
7.Capable of giving signed informed consent as described in Appendix 10.1 which includes 
compliance wi th the requi rements and restri ctions listed in the ICF and in this protocol
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
1. H ave a posit ive pregnancy test at screening or Day -1, where applicable
2.
Areplanning to beco me pregnant during the study or within 1 mo nth of study  com pletion
3. A rewomen who are lactating
4. H aveknown allergi es to selpercatinib -ordabigatran -related com pounds or any  
components of the formulat ion of selpercat inib or dabigatran, or history  of significant 
atopy
5.Have a history  of allergic react ions to medicat ions or food products
6. H avea clinically  significant abnormal ity of blood p ressure and/or pulse rate as 
determined by the invest igator
7. H aveknown bleeding disorder including prior personal or familiar history  of abnorm al 
bleeding, hereditary  or acqui red coagul ation or pl atelet disorder ,or abnorm al coagul ation 
test ( prothrombin t ime/internati onal normalized ratio or partial thromboplastin 
time/ activated partial thromboplast in time greater than ULN ) resul t at screening
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
218. C linically significant abnormalit ies on ECG as determined by the invest igator or 
prolongati on of  the QTcB or QTcF >450msec on more than 1 ECG obtained at screening
9.Have clinically significant active cardio vascular disease or history  of myocardial  
infarction wit hin 6 months prior to the pl anned start of s elpercat inib
10. H ave a history  or presence of cardio vascular, res piratory , renal, gastrointest inal, 
endocrine, hematological, or neurological disorders capable of significant ly altering the 
absorpti on, m etabo lism, or eliminat ion of drugs; of constituting a risk when taking the 
investigat ional product; or of interfering with the interpretati on of  data. Appendectomy , 
splenectomy , and cholecystectomy are considered as acceptable
11.Have a creat inine clearance <60mL/min, as calculated using the CKD -EPIequation
(Levey  et al , 2009) .
eGFR = 141 × min(S cr/K, 1)α× max(S cr/K, 1)-1.209×0.993age
× 1.018 (if female)
× 1.159 (if black)
12.
Show a history  of central  nervous system condi tions such as strokes, transient ischemic 
attacks, significant head trauma, seizures, central  nervous system infect ions, migraine, 
brain surgery , or an y other neurological condit ions that, in the opinio n of the invest igator, 
increase the risk of participat ing in the study
13. H ave a history  or presence of neuropsy chiatri c disease (e.g., manic depressive illness, 
schizophrenia, depression) considered as clini cally si gnificant by  the investi gator
14. R egularly use known drugs of abuse or show positive findings on drug screening
15. S how evidence of human immunodeficiency virus infect ion and/or posit ive human 
immunodeficiency  virus antibodies
16. P resence of hepatit is B sur face ant igen at screening or within 3 months prior to first dose 
of study  intervent ion
17. P ositive hepat itis C antibody test result at screening or within 3 months prior to first dose 
of study  intervent ion. NOTE: Participants with posit ive hepat itis C ant ibody due to pri or 
resolved disease can be enro lled if a confirmatory negat ive hepatitis C antibody  RNA test 
is obtained
18.
Positive hepat itis C antibody  RNA test resul t at screening or within 3 mo nths prior to first 
dose of study  intervent ion. NOTE: Test is opti onal and parti cipants wi th negative 
hepatitis C ant ibody  test are not required to also undergo hepati tis C RNA testi ng
19. H ave donated blood of more than 500 mL within the previous 2 months of study  
screening
20. H ave any medical condit ions, m edical history , or a re taking any medicat ions which are 
contraindicated in the dabigatran label
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
22Prior/Concomitant Therapy
21. H ave part icipated, within the last 30 days of admission, in a clinical study  involving an 
investigat ional product. If the previous invest igational product has a long half -life, 
5half-lives or 30 days (whichever i s longer) should have passed.
22. H ave previously co mpleted or withdrawn fro m this study  or any  other study  invest igating 
selpercat inib, and have previously  received the investi gational product 
23.Use of H2 blockers, proton pump inhibitors , and other drugs that affect dabigatran and/or 
selpercat inib exposure within 7 days of screening.
24. A re intending to use over -the-counter or prescript ion medicat ion, including dietary  
supplements, within 14 days pr ior to dosing and until study  discharge (apart from 
occasi onal acetaminophen (≤2 g/ 24 hours ), hormonal contraception, or hormone 
replacement therapy )
Prior/Concurrent Clinical Study Experience
25.
Are current ly enrolled in any other clinical study  involving an invest igational product or 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
Other Exclusions
26. H ave an average weekly  alcoho l intake that exceed s 21 units per week (males ≤65years 
old) and 14 unit s per week (females); 1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL 
of wine; 1.5 oz or 45 mL o f distilled spirit(s)
27. Are unwilling to stop alcohol consumpt ion 48 hours prior to each admissio nto the CRU , 
and while resident at the CRU. At all other times, participants must agree to consume no 
more than 2 unit s per day
28. A re sm okers of m ore than 10 ci garettes or e -cigarettes, or 3 cigars or 3 pipes ,per day  and 
are unable to refrain fro m smoking while resi dent at the CRU
29. C onsume excessive amounts of coffee, tea, col a, or other caffeinated beverages per day , 
or are unwilling to stop caffeine consumpt ion 48 hours prior to admission and whilst 
resident at the CRU . Excessive amount is defined as greater than 6 servings (1 serving is 
approximately  equivalent to 120 m g of caffeine) .
30.Are unable to consume a standard meal.
31. C urrent ly use or show evidence of substance abuse (including alcoho l abuse) or 
dependence within the past 6 months based on medical history  at screening visit
32. Inabilit y to com ply wi th the di etary  regimen of the CRU
33. A re Lilly  empl oyeesor are an em ployee of any  third -party  involved in the study  who 
requi re exclusio n of their emplo yees
34. A re invest igator site personnel directly affiliated wit h this study  and/or thei r immediate 
families. Immediate famil y is defined as a spouse, parent, child, or sibling, whether 
biological  or legally  adopted
35. In the opinion o f the invest igator or sponsor, are unsuitable for inclusio n in the study
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
235.3. Lifestyle Considerations
Throughout the study , parti cipants may undergo medi cal assessments and review of compliance 
with requi rements before continuing in the study .
5.3.1. Meals and Dietary Restrictions
During theconfinement period, participants will consume only food and beverages that are 
provi ded to them  by the CRU staff. Standard meals (e.g., breakfast, lunch, dinner, and snack) 
will be provided to the participants while resident at the CRU.
Dabigatran and selpercat inibwill be administered with foodusing a standardized unit meal .
The m acronutri ent com position of  the standardized meals for dabigatran and selpercat inib 
administration should be targeted to provide approximately 50% of  the cal ories from 
carbohydrates, 15% protein, and 35% fat .  The total calories for the standardized meal to be 
consumed with each dose is expected to be approximately  685 cal ories.Subjects will be 
encouraged to eat the ent ire meal.
Each component of the meal will be weighed separately and documented in grams pre and post 
meal to determine the percentage of the m ealconsum ed in grams by  the subject. The nutrit ional 
intake will be docum ented in grams and recorded in the electronic case report form (eCRF) .
Parti cipants will completethestandard ized
meal 30 minutes prior to administration of study  
intervent ionand partici pants shoul d eat thi s meal  in 30 minutes or l ess. No addi tional food 
shoul d be allo wed for at l east 4 hours after drug administration.
5.3.2. Caffeine, Alcohol, and Tobacco
Participants will abst ain fro m ingest ing caffeine -or xanthine -containing products (e.g., coffee, 
tea, cola drinks, and chocolate) for 48 hours prior to admissio n unt il after discharge from  the 
CRU
Participants will abstain from alcohol for 48 prior to admissio n unt il after discharge from  the 
CRU .
Parti cipants who use tobacco products will be instructed that use of nicotine -containing products 
(including nicotine patches) will not be permitted while they are in the clinical unit. 
5.3.3. Activity
Parti cipants w ill abstain from strenuou s exercise for 48 hours before each blood collect ion for 
clinical laboratory  tests. Parti cipants m ay parti cipate i n light recreational act ivities during the 
study (e.g., watching televisio n, reading).
5.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently assigned to study  interventi on. 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
24Individuals who do not meet the criteria for participation in this study  (screen failure) may notbe 
rescreened. Repeating o f laborator y tests during the screening period or repeating screening tests 
to com ply wit h the protocol designated screening period does not constitute rescreening.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
256. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to /used by a study  parti cipant 
according to the study  protocol .
6.1. Study Interventions Administered
Table JZJV. 1.Study Interventions Administered
Study Intervention Selpercatinib Dabigatran etexilate
Dosage Formulation Capsule Capsule
Unit dose strength(s)/Dosage 
Level(s)2 80-mg capsule s
(160 mg selpercatinib )150-mg capsule
Route of Administration Oral Oral
Dosing Instructions 2 capsules taken 
on Day  81 capsule taken on Day 1
and 
1 capsule taken on Day 8
6.1.1. Administration Details
A single oraldose of dabigatran etexilate 150 mg will be administered in the morning of Day  1
with approximately 240 mL of room temperature water while in a sitting posi tion. On the 
morning o f Day 8, a single dose of dabigatran etexilate 150 mg and selpercat inib160mg will be 
administered orally wit h approximately 240 mL of room temperature water while in a sitt ing 
position. Parti cipants will not be allowed t o lie supine for 2hours after dosing, unless clinically 
indicated or for study  procedures.
Dabigatran etexilate and selpercat inib capsules should be swallowed whole. Participants should 
not break, crush, chew, or empt y the contents of either capsule.
On d osing days, p articipants will adhere to meal restrict ions as outlined in Sect ion 5.3.1 .
6.2. Preparation/Handling/Storage/Accountability
1.The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2.Only participants enrolled in the stud y may receive study  intervent ion and only 
authori zed si te staff may  supply  or administer study  intervent ion. All study  intervent ion 
must be stored in a secure, environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordance wit h the l abeled storage conditions with access limited to 
the invest igator and authorized site staff.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
263.The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and rec ord m aintenance 
(i.e., recei pt, reconciliat ion, and final disposit ion records).
4.The invest igator or designee will return all unused study interventions to Lilly or its 
designee at the end of the study . In som e cases, si tes m ay destroy  the m aterial if, duri ng 
the CRU select ion, the evaluator has verified and documented that the site has 
appropriate facilit ies and written procedures to dispose of clinical materials .
6.3. Measures to Minimize Bias: Randomization and Blinding
This is an open -label study . There i s no bias as the primary endpo int is PK and object ive in 
measure.
6.4. Study Intervention Compliance
Participants are dosed at the site andwill receive study  intervent ion directly from the investigator 
or desi gnee, under medical supervisio n. The date and time of e ach dose administered in the clinic 
will be recorded in the source documents and recorded in the e CRF. The dose of study  
intervent ion and study  parti cipant i dentification will be confirmed at the time of dosing by a 
member of the study  site staff other tha n the person administering the study  intervent ion. Study  
site personnel will examine each part icipant’s mouth to ensure that the study  intervent ion was 
ingested.
6.5. Concomitant Therapy
Any medicat ion or vaccine (including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the study  must be recorded along wit h:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency for concomitant therapy  of special  
interest
The medical  monitor shoul d be contacted if there are any  questi ons regarding concomitant or 
prior therapy .
Parti cipants must abstain fro m taking prescript ion or nonprescript ion drugs (including vitamins 
and dietary  or herbal supplements) within 14 days before the start of study  intervent ion unt il 
discharge from  the study .
Acetaminophen , atdoses of ≤ 2grams/ 24 hours , is permitted for use at the discret ion of the 
investigator for the treatment of headache, etc . Contraceptive medicat ion is permitted as per the 
contraception requirements ( Appendix 10.4), and horm one repl acement therapy  is also allowed.
Other medication may be considered on a case -by-case basis by the investigator in consultation 
with the Lilly clinical pharmaco logist (CP)/c linical research phys ician (CRP), or designee.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
276.6. Dose Modification
Dose m odificat ion is not permitted in this study .
6.7. Intervention after the End of the Study
Not applicable.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
287. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Parti cipants discont inuing from the study  prem aturely for any  reason m ust complete and fo llow-
up procedures per Sectio n 1.3of this protocol .
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a participant to perm anent ly discont inue (definit ive 
discontinuat ion) study  intervent ion. If study  intervent ion is definit ively discont inued, the 
participant will remain in the study  to be evalu ated for safet y. See the SoA for data to be 
collected at the time of discont inuat ion of study  intervent ion and fo llow-up and for any  further 
evaluat ions that need to be com pleted.
Study  intervent ion will be discontinued for a participant if liver chemistr y stopping cri teria are 
met.
Phase 1 Liver Chemistry Stopping Algorithm
Abbreviations: ALT = alanine transaminase; INR = international normalized ratio; SAE = serious adverse event; 
ULN = upper limit of normal.
Liver Safety : Suggested Act ions and Follow-up Assessments can be found in Appendix 10.6.
A participant who me ets ei ther bulleted criterion following single ECG assessment should have 
ECG repeated . Ifthe parti cipant still meets either bulleted criterion they  will be withdrawn from  
the study .Continue Study Treatment 
Discontinue Study Treatment 
*INR value not applicable to subjects on anticoagu lants ALT ≥3xULN No
Yes
Must refer to Liver Safety Required Actions and Follow up Assessm ents  section in the Appendix
Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measured*
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
29QTc, QTcB, QTcF >500 msec
Change from baseline: QTc >60 msec
If a clinically significant finding is ident ified (including, but not limited to changes fro m baseline 
in QTcusing Bazett’s form ula or QTcF )after enrollment, the invest igator or qualified designee 
will determine if the participant can continue in the study andif any change in participant
management is needed .This review of the ECG printed at the time o f collect ionmust be 
docum ented .Any new clinically  relevant finding shoul d be reported as an AE.
See the SoA for data to be collected at the time of intervent ion discontinuation and fo llow-up and 
for any  further evaluat ions that need to be completed.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study :
at any  time at his/her own request 
at the request of his/her designee (for example, parents or legal guardian)
at the discretion of the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons
if the participant beco mes pregnant during t he study
if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study
Discontinuati on is expected to be uncommo n.
At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in the S oA. See theSoA for data to be collected at the time of study  
discontinuat ion and fo llow-up and for any  further evaluat ions that need to be completed .The 
participant will be permanent ly discont inued both fro m the study  intervent ionand fro m the study  
at that time .
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consent .If a participant
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested ,
and the invest igator must document this in the site study records .
7.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  treatm ent unl ess 
there are extenuating cir cumstances that make it medically necessary for the participant to 
continue on study  treatm ent. If the investigator and the sponsor CRP agree it is medically 
appropriate to continue, the invest igator must obtain documented approval fro m the sponsor CRP 
to allow the inadvertently enrolled participant to continue in the study  with or wi thout treatm ent 
with invest igational product. Safet y follow-up is as outlined in Sect ion 1.3(Schedule of 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
30Activities), Secti on 8.2(Safet y Assessments) , and Secti on 8.3(Adverse Events and Serious 
Adverse Events) of the protocol .
7.3. Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.Site personnel are expected to 
make diligent attempts to conta ct participants who fail to return for a scheduled visit or were 
otherwi se unable to be fo llowed up by the site.
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendix 10.1.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
318. Study Assessments and Procedures
●Study  procedures and their timing are summarized in the SoA. Protocol waiver s 
or exempt ions are not allowed.
●Immediate safet y concerns shoul d be discussed with the s ponsor immediately  
upon occurrence or awareness to determine if the participant should continue or 
discontinue study  interventi on.
●Adherence to the study  design requi rements, including those specified in the SoA, 
is essent ial and requi red for study conduct.
●All screening evaluat ions must be com pleted and reviewed to confirm that
potenti al participant s meet all  eligibili ty criteria. The invest igator will maint ain a 
screening log to record details o f all participant s screened and to confirm 
eligibilit y or record reasons for sc reening failure, as applicable.
8.1. Efficacy Assessments
Not applicable.
8.2. Safety Assessments
8.2.1. Physical Examinations
●Physical examinat ions shoul d be conducted according to the SoA ( Section 1.3). 
●A fullphysical examinat ion will include, at a minimum, assessments of the 
cardiovascular, respiratory , gastrointestinal ,and neurol ogical systems. Hei ght and 
weight will also be measured and recorded.
●Invest igators should pay special attention to clinical signs related to previous 
serious illnesses.
8.2.2. Vital Signs
●For each participant , vital signs m easurements shoul d be conducted according to 
the SoA (Secti on1.3).
Blood pressure and pulse rate should be measured singly after at least 5 minutes supine. 
For each individual participant , the same cuff size should be used throughout the study  
for the m easurements of blood pressure . The cuff should be attached to the participant’s
dominant arm.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of 
dizziness or posture -induced symptoms. Where orthostatic measurements are required, 
participants shoul d be supine for at l east 5 minutes and then partici pants will stand, and 
standing blood pressure will be measured after 2 minutes , but no longer than 3 minutes. If 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
32the participant feels unable to stand, supine vital signs only will be collected. Additional 
vital signs may  be measured if warranted.
8.2.3. Electrocardiograms
●For each participant, single 12-lead ECG s will be obtained as outlined in the SoA 
(see Section 1.3). Refer to Section 7for QTc withdrawal criteria and any 
additional QTc readings that may be necessary.
Electrocardiograms must be recorded before collecting any blood samples. Participants 
must be supine for approximately 5 to 10 minutes before ECG collect ion and remain 
supine but a wake during ECG collect ion. El ectrocardi ograms m ay be obtained at 
additional times, when deemed clinically necessary. All ECGs recorded should be stored 
at the investigational site.
Electrocardiograms will be interpreted by  the investi gator at the site as soon after the time 
of ECG collect ion as possible, and ideally while the participant is st ill present, to 
determine whether the participant meets entry  criteria at the rel evant visit(s) and for 
immediate participant management, should any clinically releva nt findings be ident ified.  
If a clinically significant finding is ident ified (including, but not limited to, changes in 
QT/QTc interval fro m baseline) after enrollment, the invest igator will determine if the 
participant can continue in the study . The inv estigator, or qualified designee, is 
responsible for determining if any change in part icipant management is needed and must 
docum ent his/her review of the ECG printed at the time of collect ion. Any new clinically 
relevant finding should be reported as an AE.
8.2.4. Clinical Safety Laboratory Assessments
●See Appendix 10.2 for the list of clinical laboratory  tests to be perform ed and to 
the SoA for the timing and frequency .
●The invest igator must review the laboratory report, document this review, and 
record any  clinically  relevant changes occurring during the study  in the AE 
section of the eCRF. The laboratory  reports m ust be filed wit h the source 
docum ents.
●All laboratory  tests wi th values considered clinically  significantly abnorm al 
during participat ion in the study after the last dose of study intervent ion shoul d be 
repeated until the values return to normal or baseline or are no longer considered 
clinica lly significant by  the investi gator or m edical m onitor.
○If such values do not return to normal/baseline wit hin a peri od of  time judged 
reasonable by the invest igator, the etio logy shoul d be ident ified, and the 
sponsor notified.
○All protocol -requi red laboratory  assessments, as defined in Appendix 10.2,
must be conducted in accordance wit h the laboratory  manual and the SoA.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
33○If laboratory  values fr om non-protocol  specified l aboratory  assessments 
perform ed at the inst itution’s l ocal laboratory  require a change in participant 
management or are considered clinically  significant by  the invest igator (e .g., 
SAE or AE), then the resul ts must be recorded in the eCRF.
8.2.5. Safety Monitoring
The Lilly CPor CRP/sci entist will mo nitor safet y data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures. The Lilly CPor 
CRP will periodically review the fo llowing data:
trends in safety  data
laboratory  analy tes including hematol ogy and chemistry
When appropriate, the Lilly CPor CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area p hysician or clinical research scient ist.
8.2.5.1. Hepatic Safety
Close hepat ic monitoring
Laboratory  tests (Appendix 10.6), including AL T, AST , ALP, TBL, direct bilirubin , gamma -
glutamyl  transferase , and creatine kinase , shoul d be repeated wi thin 48 to 72 hours to confirm 
the abnormalit y and to determine if it is increasing or decreasing, if one or more of these 
condi tions occur:
If a participant with baseline 
resul ts of ... develops the fo llowing elevat ions:
ALT or AST <1.5 ×ULN ALT or AST ≥3× ULN
ALP <1.5 ×ULN ALP ≥2×ULN
TBL <1.5 ×ULNTBL ≥2×ULN (except for patients with 
Gilbert’s syndrome)
ALT or AST ≥1.5 ×ULN ALT or AST ≥2×baseline
ALP ≥1.5 ×ULN ALP ≥2×baseline
TBL ≥1.5 ×ULNTBL ≥2×baseline (except for patients with 
Gilbert’s syndrome)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  the invest igator in consultat ion with 
the Lilly -designated m edical mo nitor. At a minimum, this eval uation shoul d include physical 
examinat ion and a thorough medical history , including symptom s, recent illnesses (for example, 
heart failure, systemic infect ion, hypotension, or seizures), recent travel, history  of concomi tant 
medicat ions (including over -the-counter), herbal and dietary  supplements, history  of alcoho l 
drinking and other substance abuse. 
Initially, monitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the participant ’s clinical co ndition and hepat ic biochemical tests. 
Subsequently , the frequency  of monitoring may  be lowered to once every  1 to 2 weeks, if the 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
34participant ’s clinical condit ion and laboratory results stabilize. Moni toring of AL T, AST , ALP, 
and TBL  shoul d cont inue unt illevels norm alize or return to approximate baseline levels.
Com prehensive hepatic evaluation  
A comprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m ore of these condit ions occur:
If a participant with base line 
resul ts of... develops the fo llowing elevat ions:
ALT or AST <1.5 ×ULN ALT or AST ≥3× ULN wi th hepat ic signs/symptoms*, or
ALT or AST ≥5×ULN
ALP <1.5 ×ULN ALP ≥3×ULN
TBL <1.5 ×ULN TBL ≥2×ULN (except for patients with Gilbert’s syndro me)
ALT or AST ≥1.5 ×ULN ALT or AST ≥2×baseline wit h hepat ic signs/symptoms*, or
ALT or AST ≥3×baseline
ALP ≥1.5 ×ULN ALP ≥2×baseline
TBL ≥1.5 ×ULN TBL ≥1.5 ×baseline (except for patients with Gilbert’s 
syndro me) 
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
and/o r eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin t ime/internat ional normalized ratio ; 
tests for viral hepatit is A, B, C, or E; tests for autoimmune hepat itis; and an abdo minal imaging 
study  (for example, ul trasound or computed tomography scan). 
Based on the participant ’shistory  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for hepatit is D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxico logy screen, W ilson ’s disease, blood alcohol levels, urinary  ethyl  glucuroni de, and 
serum  phosphat idylethano l. Based on the circumstances and the invest igator ’s assessment of the 
participant ’s clinical condit ion, the invest igator should consider referring the parti cipant for a 
hepatol ogist or gastroenterologist consultation, magnet ic resonance cho langiopancreatography , 
endoscopi c retrograde cholangiopancreatography , cardi ac echocardi ogram , or a liver biopsy .  
Additional hepatic data collection (hepatic safety eCRF) in study participants who have 
abnormal liver  tests during the study:
Addit ionalhepatic safet y data collect ion in hepat ic safet y eCRF sshoul d be perform ed in study  
participants who meet 1 or more of the fo llowing 5 condi tions:
1.Elevat ion of serum AL T to ≥5× ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5 × ULN)
In parti cipants wi th baseline ALT ≥1.5 ×ULN, the thresho ld is ALT 
≥3×baseline on 2 or more consecut ive tests
2.Elevated TBL  to ≥2×ULN (if baseline TBL  <1.5 ×ULN) (except for cases of known 
Gilbert ’s syndrom e)
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
35In parti cipants wi th baseline TBL  ≥1.5 × ULN, the thresho ld should be TBL  
≥2×baseline
3.Elevat ion of serum ALP to ≥2×ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5 ×ULN)
In parti cipants wi th baseline ALP ≥1.5 ×ULN, the thresho ld is ALP ≥2× baseline 
on 2 or more consecutive blood tests
4.Hepati c event consi dered to be an SAE
5.Discontinuati on of  study  drug due to a hepati c event 
NOTE : the interval between the 2consecutive blo od tests should be at least 2 day s.
8.3. Adverse Events and Serious Adverse Events
Product Complaint s are covered in Sect ion 8.3.6 .
Adverse events will be reported by  the parti cipant (or, when appropri ate, by  a caregiver, 
surrogate, or the participant ’slegally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the participant to discont inue the study  intervent ion (see Section 7).
8.3.1.
Time Period and Frequency for Collecting AE and SAE In formation
All SAEs will be co llected from the signing of the ICF until participat ion in the study  has ended.
All AEs will be co llected fro m the start of interventi onuntil the follow-up visit .
Medical occurrences that begin before the start of study  interventi on but after si gning of the ICF 
will be recorded on the Adverse Event eCRF.
Although all AEs after signing the ICF are recorded by the site in the eCRF/electroni c data entry , 
SAE reporting to the sponsor begi ns after the participant has signed the ICF and has received 
study  drug. However, if an SAE occurs after signing the ICF, but prior to receiving selpercatinib , 
it needs to be reported ONLY if it is considered reasonably  possibly  related to study  procedures.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Appendix 10.3.The invest igator will 
submit any  updated SAE data to the sponsor within 24 hours of i t being available.
Invest igators are not obligated to actively seek AE sor SAE safter concl usion of the study  
participat ion. However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervent ion or study  parti cipati on, the invest igator m ust prom ptly notify  the 
sponsor .
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Appendix 10.3.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
36Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal quest ioning of the participant is the preferred method to i nquire about AE
occurrences .
8.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs will be fo llowed until reso lution, stabilizat ion,the event 
is otherwi se explained, or the participant is lost to fo llow-up (as defined in Sect ion7.3). Further 
inform ation on fo llow-up procedures is provi dedin Appendix 10.3.
8.3.4. Regulatory Reporting Requirements for SAEs
●Prom pt notificat ion by the invest igator to the sponsor of anSAE is essent ial so 
that legal obligat ions and ethical responsibilit ies towards the safet y of parti cipants 
and the safet y of a study  interventi on under clinical invest igation are m et.
●The sponsor has a legal responsibilit y to notify both the l ocal regul atory  authori ty 
and other regulatory  agencies about the safet y of a study  interventi on under 
clinical invest igation. The sponsor will comply wit h country -specific regulatory  
requi rements rel ating to safety reporting to the regulatory authorit y, IRB/IEC , and 
investigators.
●An invest igator who receives an invest igator safety report describing anSAE or 
other specific safet y informat ion (e.g., summary or list ing of SAEs) from the 
sponsor will review and then file it alo ng with th e IBand will notify  the IRB/ IEC, 
if appropriate according to local requirements.
8.3.5. Pregnancy
●Details o f all pregnancies in female participants and , if indicated, female partners 
of male partici pants will be co llected after the start of study intervent ion and unt il 
the follow-up visi t.
●If a pregnancy  is reported, the investigator should inform the sponsor within 
24hours of learning of the pregnancy and should follow the procedures outlined 
in Appendix 10.3.
●Abnorm al pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
●Pregnancy (maternal or paternal exposure to investigat ional product ) does not 
meet the definit ion of an AE. However, to fulfill regulatory  requi rements, any  
pregnancy should be reported fo llowing the SAE process described in 
Appendix 10.4 to collect data on the outcome for both mother and fetus.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
378.3.6. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the ide ntity, qualit y, durabilit y, reliabilit y, safety, effect iveness ,or performance of a 
study interventi on. 
The s ponsor collects product complaints on investigational products and drug delivery systems 
used in clinical studies in order to ensure the safet y ofstudy  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Parti cipants will be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the s ituation can be assessed.
NOTE: AE s/SAE sthat are associated with a product complaint will also fo llow the processes 
outlined in Sect ion 8.3.3 and Appendix 10.3 of the protocol .
8.3.6.1. Time Period for Detecting Product Complaints
●Product complaints that resul t in an AEwill be detected, documented, and 
reported to the sponsor during all periods of the study in which the drug is used.
●If the inv estigator l earns of any product complaint at any  time after a participant 
has been discharged from the study , and such incident is considered reasonably 
related to a drug provided for the study, the investigator will pro mptly notify  the 
sponsor.
8.3.6.2. Prompt Reporting of Product Complaints to Sponsor
●Product complaints will be reported to the sponsor within 24 hours after the 
investigator becomes aware of the co mplaint.
●The Product Com plaint Form  will be sent to the sponsor by  email.If email is 
unavailable, then faxshoul d be ut ilized .
8.3.6.3. Follow -up of Product Complaints
●Follow-up applies to all participants, including those who discont inue study  
intervent ion.
●The invest igator is responsible for ensuring that follow -up includes any 
supplemental  investigations as indicated to elucidate the nature and/ or causalit y of 
the product complaint .
●New or updated informat ion will be recorded on the originally co mpleted form 
with all changes signed and dated by the invest igator and submitted to the 
sponsor .
8.3.6.4. Regulatory Reporting Requirements for Product Complain ts
●As requi red by l ocal regulat ions, the invest igator will report to their IRB/IEC any 
unant icipated adverse device effect or unant icipated probl em that resul ted in an SAE, or 
any product complaint that could have led to an SAE had precaut ions not been t aken.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
388.4. Treatment of Overdose
For the purposes of this study , an overdose of selpercatinib or dabigatran etexilate is considered 
as any dose higher than the dose assigned. There i s no specific antidote for selpercat inib.
The ant idote to dabigatran is idaruci zumab and may  be used in case of overdose.
In the event of an overdose, the invest igator/treating physician shoul d:
1.Contact the medical monitor immediately .
2.Closely  monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities unt il study  
intervent ioncan no longer be detected sy stemically  (at least5days).
3.Docum ent the quanti ty of the excess dose as well as the duration of the overdose in the 
eCRF.
4.In the case of emergency  uncontrolled bleeding as a direct consequence of dabigatran, 
urgen t referral for treatm ent wi th idarucizumab shoul d be considered .
Decisio ns regarding dose interruptions will be made by the invest igator in consultat ion with the 
medical monitor based on the clinical evaluat ion of the participant.
8.5. Pharmacokinetics
●At the times and visits specified in the SoA , venous blood sample s of 
approximately  2mL each will be co llected to determine the plasma
concentrations of selpercat iniband dabigatran . 
●A maximum of 3samples m ay be collected at additional t ime po ints during the 
study  if warranted and agreed upon between the investigator and the sponsor.
●Instructi ons for the collect ion and handling of bio logical samples will be provided 
by the sponsor. The actual dat e and time (24- hour clock time) of each sample will 
be recorded.
8.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor.
Concentrations of selpercat iniband dabigatran will be assayed using a validated liquid 
chromatography  with tandem  mass spectrom etrymethod.
Bioanaly tical samples collected to m easure invest igational product concentrations will be 
retained for a maximum o f 1 year following l ast parti cipant vi sit for the study .  
8.6. Pharmacodynamics
Pharmacodynamic parameters a re not evaluated in this study .
8.7. Genetics
A blood OR saliva sample for DNA i solation will be co llected fro m participants. 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
39See Appendix 10.5 for inform ation regarding genetic research and Appendix 10.1 fordetails 
about sample retenti on and c ustody .
8.8. Biomarkers
Biomarkers are not eval uated in thi s study .
8.9. Immunogenicity Assessments
Not applicable for this study .
8.10. Health Economic s
This sect ion is not applicable for this study.
C O N FI D E N TI A L Pr ot oc ol  J 2 G -M C -J ZJ V (a) 
4 0 9. St atistic al C o nsi der ati o ns 
9. 1. St atistic al H y p ot heses 
T he pri mar y  o bject i ve varia bles will be e val uate d t o assess t he p ote ntial dr u g -dr u g i nteracti o n. 
All tests a n d/ or esti mat i o n statistics will n ot be c o nfir mat or y  b ut will c o ntri b ute t o a b o d y  of  
e vi de nce t o s u p p ort fi nal c o ncl usi o ns. 
9. 2. S a m ple Size Deter mi n ati o n 
Ap pr o xi matel y   will be e nr olle d s o t hat a p pr o xi matel y  c o m plete 
t h e st u d y . T o e val uate t he effect of sel percati ni b o n P -g p acti vit y,  i t i s i m p orta nt t hat t he rati o of 
ge o m etri c m ea ns is est i mate d wit h reas o na ble precisi o n. 
 
 
9. 3. P o p ul ati o ns f or A n al yses 
The f o ll o wi n g p o p ul at i o ns are defi ne d: 
P o p ul ati o n Descri pti o n 
E ntere d All partici pa nts w h o si g n t he I C F .
E nr olle d/I nte nt -t o -Treat All partici pa nts assi g ne d t o treat me nt, re gar dless of w het her t he y  
ta ke a n y  d oses of i n vesti gati o nal pr o d uct , or if t he y ta ke t h e 
c orrect treat me nt. 
S af et y All partici pa nts assi g ne d t o da bi gatra n a n d w h o ta ke at least 
1d ose. 
P har mac o ki net ic A nal ysis All partici pa nts w h o recei ve d at least 1 d ose of da bi gatra n a n d 
ha ve e val ua ble P K. 
9. 3. 1. St u d y P artici p a nt Dis p ositi o n 
A detaile d descri pti o n of  p arti ci pa nt dis p osi ti o n will be pr o vi de d at t he e n d of t he st u d y .
9. 3. 2. St u d y P artici p a nt C h ar acteristics 
T he parti ci pa nt’s a ge, se x, a n d ot her de m o gra p hic c haracterist ic s will be rec or de d a n d 
s u m marize d. De m o gra p hic c haracterist ic s m a y be c o nsi dere d i n t he i nter pretati o n of P K a n d 
safet y a nal yses. 
9. 3. 3. Tre at me nt C o m pli a nce 
T he d ate a n d ti me of d osi n g will be rec or de d a n d liste d .C CI C CI C CI 
C CI 
C O N FI D E N TI A L Pr ot oc ol  J 2 G -M C -J ZJ V (a) 
4 1 9. 4. St atistic al A n al yses 
Stati st ical a nal ysis o f t his st u d y  will  b e t he res p o nsi bilit y of  t h e sp o ns or or i ts desi g nee. 
P har mac o ki net ic a nal yses will be c o n d ucte d o n data fr o m all partici pa nts w h o recei ve dat least 1
d ose of t he i n vest i gat i o nal pr o d uct a n d ha ve e val ua ble P K .
S af et y a nal yses will be c o n d ucte d f or all e nr o lle d partici pa nts w h o recei ve d at l east 1 d ose of 
da bi gatra n , w het her or n ot t he y  c o m plete d all pr ot oc ol re q uire me nts. 
A d dit i o nal e x pl or at or y  a nal yses of t he data will be c o n d ucte d as dee me d a p pr o pri ate. 
9. 4. 1. S afet y A n al yses 
9. 4. 1. 1. Cli nic al E v al u ati o n of S afet y 
All i n vest i gat i o nal pr o d uct a n d pr ot oc ol pr oce d ure A Es will be liste d, a n d if t he fre q ue nc y o f 
e ve nts all o ws, safet y data will be s u m marize d usi n g descri pt i ve met h o d ol o g y .
T he i nci de nce of A Es f or eac h tr e at m e nt will be prese nte d b y  s e v eri t y  a n d b y ass oci at i o n wi t h  
i n vesti gat i o nal pr o d uct as percei ve d b y  t he i n vesti gat or. A d verse e ve nts re p orte d t o occ ur pri or 
t o e nr oll me nt will be dist i n g uis he d fr o m t h ose re p orte d as ne w or i ncrease d i n se verit y d uri n g t h e 
st u d y .Eac h A E will be classifie d b y t he m ost s uita ble ter m fr o m t h e m e dical re g ulat or y  
di ct i o nar y .
T he n u m ber of i n vest i gat i o nal pr o d uct -relate d S A Es will be re p orte d. 
9. 4. 1. 2. St atistic al E v al u ati o n of S afet y 
S af et y para m eters t hat will be assesse d i ncl u de sa fet y  l a b orat or y  para meters, vi t al  si g ns, a n d 
E C G para meters. T he para meters will be liste d a n d s u m marize d usi n g sta n dar d descri pt i ve 
statist ics. A d dit i o nal a nal ysis will be perf or me d if warra nte d u p o n re vie w of t he data. 
9. 4. 2. P h ar m ac o ki netic A n al yses 
9. 4. 2. 1. P K P ar a met er Esti m ati o n 
P har mac o ki net ic para meter esti mates will be calc ulate d b y sta n dar d n o nc o m part me nt al  m et h o ds. 
T he pri mar y  P K para m et ers f or a nal ysis of da bi gatra n will be: Cm a x a n d A U C( 0 -∞) .Ot her 
n o nc o m part me nt al  para m eters, s uc h as tma x , t 1/ 2 , a p pare nt t ota l b o d y  cleara nce of dr u g 
cal c ulate d after e xtra vasc ular a d mi nistrati o n, a n d a p pare nt v ol u me of distri b ut i o n d uri n g t he 
ter mi nal p hase after e xtra vasc ular a d mi nistrati o n, ma y be re p orte d as a p pr o priate. 
N o nc o m part me nt al  P K para meters will als o be calc ulate d f o r sel percat i ni b .
9. 4. 2. 2. P K St atistic al I nfere nce 
P har mac o ki net ic para meters will be e val uate d t o esti mate D DI f o r da bi gatra n. L o g -tra nsf or m e d 
Cm a x a n d A U C ( 0 -∞) para meters f or da bi gatra n will be e val uate d se paratel y .  
 C CI 
C O N FI D E N TI A L Pr ot oc ol  J 2 G -M C -J ZJ V (a) 
4 2  
  
 
P har mac o ki net ic para meters will be s u m marize d usi n g descri pt i ve statist ic s. 
9. 4. 3. P h ar m ac o d y n a mic A n al yses 
N ot a p plica ble f or t his st u d y .
9. 4. 4. P h ar m ac o ki netic/ P h ar m ac o d y n a mic A n al yses 
N ot a p plica ble f or t his st u d y .
9. 5. I nteri m A n al yses 
N o i nt eri m a nal yses are pla n ne d f or t his st u d y . If  a n u n pla n ne d i nteri m a nal ysis is dee me d 
necessar y  f or reas o ns ot her t h a n a safet y c o ncer n, t he pr ot oc ol m ust be a me n de d. 
9. 6. D at a M o nit ori n g C o m mittee 
N o data m o nit ori n g c o m mittee is re q uire d f or t his st u d y .C CI 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
4310. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerati ons
10.1.1. Regulatory and Ethical Considerations
●This study  will be conducted in accordance wit h the protocol and with the 
following:
○Consensus ethical principles derived from international guidelines including 
the Decl aration of Helsinki and Council for Inte rnational Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines
○Applicable ICH GCP Guidelines
○Applicable laws and regulations
● The protocol, protocol amendments, ICF, IB, and other relevant documents (e .g., 
advert isements) must be submi tted to an IRB/IEC by  the investi gator and 
reviewed and approved by the IRB/IEC before the study  is init iated.
●Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study  design, except for changes 
necessary  to eliminate an immediate hazard to study  parti cipants.
●The invest igator will be responsible for the fo llowing:
○Provi ding wri tten summaries of the status of the study  to the IRB/IEC 
annually or more frequently in accordance with the r equirements, policies, and 
procedures established by the IRB/IEC
○Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required 
by IRB/IEC procedures
○Provi ding oversight of the conduct of the study
 at the site and adherence to 
requi reme nts of 21 CFR, ICH guidelines, the IRB/IEC, European regulat ion 
536/2014 for clinical studies (if applicable), and all other applicable local 
regul ations
●Invest igator sites are compensated for participat ion in the study as detailed in the 
clinical trialagreement .
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators are 
responsible for providing informat ion on financial interests during the course of the study  and for 
1 year after complet ion of the study .
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
4410.1.3. Informed Consent Process
●The invest igator or his/her re presentative will explain the nature of the study , 
including the risks and benefit s,to the participant or his/her l egally  authori zed 
representative and answer all questi ons regarding the study .
●Parti cipants m ust be inform ed that thei r parti cipat ion is v oluntary . Partici pants or 
their legally authori zed representative will be required to si gn a statem ent of 
inform ed consent that meets the requirements of 21 CFR 50, local regulat ions, 
ICH guidelines, Health Insurance Portabilit y and Accountabilit y Act 
requirements, where applicable, and the I RB/IEC or study  center.
●The m edical  record m ust include a statem ent that wri tten inform ed consent was 
obtained before the participant was enter ed in the study  and the date the written 
consent was obtained. The authori zed person obtaining the informed consent must 
also sign the ICF.
●Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during 
their parti cipat ion in the study .
●A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s 
legally authorized representati veand is kept on file.
10.1.4. Data Protection
●Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant 
records ,datasets ,or tissue samples that are transferred to the sponsor will contai n 
the identifier only; participant names or any  informat ion which would make the 
participant i dentifiable will not be transferred.
●The parti cipant must be inform ed that hi s/her personal  study -related data will  be 
used by the sponsor in accordance wit h local data protecti on law. The level o f 
disclosure m ust al so be explained to the participant who will be required to give 
consent for their data to be used as described in the informed consent .
●The parti cipant must be inform ed that hi s/her m edical  records may be examined 
by Clinical Qualit y Assurance auditors or other authorized personnel appo inted by  
the sponsor, by  appropri ate IRB/IEC m embers, and by  inspectors from regulatory  
authori ties.
●The sponsor has processes in place to ensure data protection, i nform ation securit y,
and data integrit y. These processes include appropriate contingency plan(s) for 
appropriate and timely  response in the event of a data securit y breach.
10.1.5. Dissemination of Clinical Study Data
Communication of Suspended or Terminated Dosing
If a decisio n is taken to suspend or terminate dosing in the study due to safet y findings, this 
decisio n will be communicated by Lilly to all investigators (for example, by phone and/or email) 
as soon as possible. It will be a requirement that inves tigators respond upon receipt to confirm 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
45that they  understand the communication and have taken the appropriate action prior to further 
dosing any participants with study  intervent ion. Any invest igator not responding will be 
followed up by  Lilly personnel p rior to any  further planned dosing. If a dose is planned 
imminent ly, Lilly personnel will immediately, and continually, use all efforts to reach 
investigators until contact is made and instructions verified.
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publi clyavailable websites where required by  local law or regul ation.
Data 
The sponsor does not proactively  share data from  Phase 1 clinical tri als. Requests for access to 
Phase 1 clinical trial da ta are evaluated on a case by  case basis taking into considerat ion the 
abilit y to anonymize the data and the nature of the data collected.
10.1.6. Data Quality Assurance
●All participant data relat ing to the study  will be recorded on printed or electronic 
eCRF unless transmitted to the sponsor or designee electronically  (e. g., laboratory  
data). The investigator is responsible for verifying that data entries are accurate 
and correct by  physically  or electronically  signing the eCRF.
●The invest igator must maintain accurate docum entati on (source data) that 
supports the informat ion entered in the eCRF.
●The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, 
and regulatory  agency inspect ions and provide direct a ccess to source data 
docum ents.
●Moni toring details describing strategy  (e.
g., risk -based init iatives in operations 
and qualit y such as Risk Management and Mit igation Strategies and Analyt ical 
Risk-Based Monitoring), methods, responsibilit ies,and requirements, including 
handling of nonc ompliance issues and monitoring techniques are provided in the 
Moni toring Pl an.
●The sponsor or designee is responsible for the data management of this study  
includin g qualit y checking of the data.
●The sponsor assumes accountabilit y for acti ons delegated to other individuals 
(e.
g., contract research organizat ions).
●Study  monitors will perform  ongoing source data verification to confirm that data 
entered into the e CRF by authorized site personnel are accurate, complete, and 
verifiable fro m sourc e docum ents; that the safet y and ri ghts of  parti cipants are 
being protected; and that the study  is being conducted in accordance with the 
currently approved protocol and any other study  agreem ents, ICH GCP, and all 
applicable regu latory  requi rements.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
46●Records and docum ents, including signed ICFs, pertaining to the conduct of this 
study  must be retained by  the invest igator for the time period outlined in the 
clinical trial agreement unless local regulat ions or inst itutional policies requi re a 
longer retenti on peri od. No records m ay be destroyed during the retention period 
without the wri tten approval  of the sponsor. No records may be transferred to 
another location or party  without wri tten notification to the sponsor .
●In addit ion, the sponsor or its repres entatives will periodically check a sample of 
the participant data recorded against source documents at the study  site. The study  
may be audited by the sponsor or its representatives, and/or regulatory  agencies at 
any time. Invest igators will be given noti ce before an audit occurs.
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the 
following:
○provi de instructi onal materi al to the study  sites, as appropriate.
○provi de training to i nstruct the invest igators and study  coordinators. Thi s 
training will give instruction on the protocol, the complet ion of the eCRFs, 
and study  procedures.
○make periodic visit s to the study  site.
○be available for consultation and sta y in contact with the study  site personnel 
by mail, tel ephone, or fax.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  will be used in this study  for the collect ion of eCRF data. The 
investigator maintains a separate source for the data entered by  the invest igator or designee into 
the sponsor -provided electroni c data capture system. The in vestigator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the eCRF .
Data collected via the sponsor- provided data capture system swill be stored at a third-party . The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laborat ory test data, will be stored electronically  in 
the central  vendor’s database system and electronic transfers will be provi ded to the invest igator 
for review and retent ion. Data will subsequent ly be transferred fr om the central  vendor to the 
sponsor data warehouse.
Data from co mplaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management sy stem .
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
4710.1.7. Source Documents
●Source documents provide evidence for the existence of the participant and 
substant iate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
●Data reported on the CRF or entered in the electronic CRF that are transcribed 
from source docum ents m ust be consistent with the source documents or the 
discrepancies must be explained. The invest igator may need to request previous 
medical records or transfer records, depending on the study . Also, current m edical 
records m ust be available.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will  be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
●Failure of the invest igator to co mply with the protocol , the requi rements of the 
IRB/IEC or local healt h authorit ies, the sponsor ’sprocedures, or GCP guidelines
●Inadequate recruit ment of parti cipants by  the investi gator
●Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as speci fied by the applicable 
regul atory  requi rements. The investigator shall prompt ly inform  the participant and ensures
appropriate participant therapy  and/or foll ow-up.
10.1.9. Publication Policy
In accordance with the sponsor’s publication po licy, the results of this study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
4810.1.10. Long -Term Sample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
invest igation of variable response that may not be observed unt il later in the development 
ofselpercat inib.
Sample Type Custodian Retention Period After 
Last Patient Visit*
Long -term storage sam ples Sponsor or Designee 15 years
Pharmacokinet ics Sponsor or Designee 1 year 
Genet ics Sponsor or Designee 15 years
*Retention periods may  differ l ocally .
The sponsor has a right to retain a portion of submitted biopsy  tissue. Archival blo cks will be 
returned to the study  site. Slides and tissue samples collected on study  will not be returned.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
4910.2. Appendix 2: Clinical Laboratory Tests
●The tests detailed below will be performed by the local laboratory .
●Protocol -specific requirements for inclusio n or exclusio n of participants are 
detailed in Sect ion 5of the protocol.
●Addit ional tests may be performed at any  time during the study  as determined 
necessary  by the invest igator or required by loca l regul ations.
●Pregnancy testing will be conducted as detailed in the SoA (Section 1.3).
Invest igators must document their review of each laboratory  safety  report.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
50Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate (total CO 2)
Mean cell volume Chloride 
Mean cell hemoglobin Calcium 
Mean cell hemoglobin concentration Phospho rus 
Leukocytes (WBC) 
PlateletsGlucose (random )
Creatine kinase
Coagulation
   Prothrombin time (PT)
Activated partial thromboplastin time (aPTT)
International normalized ratio (INR)
Differential WBC (absolute counts) of Blood urea nitrogen (BUN)
Neutrophils Uric acid 
Lymphocy tes
Monocytes Total protein
Eosinophils Albumin
Basophils Total bilirubin
Alkaline phosphatase (ALP)
Urinalysis a Aspartate aminotransferase (AST)
Specific gravity Alanine aminotransferase (ALT)
pH Creatinine
Protein
Glucose Ethanol testing b
Ketones Urine drug screen b
Bilirubin Hepatitis B surface antigen c
Urobilinogen Hepatitis C antibody c, d
Blood HIV c
Nitrite Pregnancy test ( women of childbearing potential only )
FSH (if applicable) c
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cell; 
WBC = white blood cell.
aPerformed by dipstick.
bUrine drug screen and ethanol (urine or breath) level performed at screening, and may be repeated prior to 
admission to the clinical research unit .
cPerformed at screening only.
dParticipants with a positive hepatitis C antibody test result can have a confirmatory hepatitis C RNA test.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
5110.2.1. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
Protocol J2G- MC-JZJV Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 45 1 45
Clinical laboratory tests a 12 5 60
Pharmacokinetics -Selpercatinib 2 15 30
Pharmacokinetics -Dabigatran 2 28 56
Blood discard for cannula patency 1 1 1
Genetic sample 10 1 10
Total 202
Total for clinical purposes 210
aAdditional samples may be drawn if needed for safety purposes.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
5210.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) tem porally 
associ ated wi th the use of study  intervent ion
.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments (e .g., ECG, radio logical scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinically significant in the 
medical and scient ific judgment of the investigator (i .
e., not related to progression of 
underlying disease).
Exacerbat ion of a chronic or intermittent pre-exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  intervent ion administration even 
though it m ay have been present before the start of the study .
Signs, symp toms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken wi th possible suicidal/self -harming 
intent. Such overdose should be reported regardless of sequelae.
Events NOT Meeting the AE D efinition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
Medical or surgical procedure (e .g., endoscopy , appendectomy): the condit ion that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
53Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of th e study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met (e .g., hospitalizat ion for signs/symptoms of the disease under study , death due to 
progression of dis ease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
Results in death
Is life -threatening
The term  'life-threatening' in the definit ion of 'serious' refers to an event in which the 
participant was at ri sk of death at the time o fthe event. It does not refer to an event, which 
hypotheti cally  might have caused death, if it were more severe.
Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal
for observat ion and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complicat ions that occur during hospitalization 
are AEs. If a complicat ion prol ongs hospi talizati on or f ulfills any  other seri ous cri teria, 
the event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE shoul d be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen 
from baseline is not considered an AE.
Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This de finition is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, 
and accidental trauma (e .g., sprained ankle) which may interfere with or prevent 
everyday life f uncti ons but do not constitute a substantial disrupt ion
.
Is a congenital anomaly/birth defect
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
54Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medi cal events that may not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the 
participant or m ay requi re medical or surgi cal intervent ion to prevent one of the other 
outcom es listed in the above definit ion. These even ts shoul d usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsio ns that do not result in hospitalizat ion, or development of drug dependency or 
drug abuse .
10.3.3. Recording and Follow -upof AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (e .g., hospital progress notes, laboratory  repor ts, and diagnostics 
reports) related to the event.
The invest igator will then record all relevant AE/SAE informat ion in the eCRF.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to the sponsor or designee in lieu of completion of the AE/SAE eCRF page.
There m ay be instances when copies of medical records for certain cases are requested 
by the s ponsor or desi gnee . In this case, all participant identifiers, with the except ion of 
the participant number, will be redacted on the copies of the medical records before 
submissio n to the sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to 1 of the fo llowing categori es:
Mild: An event that is easily  tolerated by  the participant, causing minimal discomfort 
and not interfering with everyday act ivities.
Moderate: An event that causes sufficient discomfort and interferes wit h norm al 
everyday act ivities.
Severe: An event that prevents norm al every day activi ties. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category  utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
55An event is defined as ‘serious’ when it me ets at l east 1 of the predefined outcomes as 
described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relat ionship, rather than a relat ionship cannot be 
ruled out.
The invest igator will use clinical judgment to determine the rel ationship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will als o consul t the IB and/or Product Information, for marketed 
products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred, and the invest igator has 
minimal informat ion to include in the init ial report to the sponsor or designee . 
However, it is very  important that the invest igator always make an assessment of 
causalit y for every  event befo re the init ial transmission of the SAE data to the sponsor 
or desi gnee .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
inform ation and send anSAE follow -up report wi th the updated causalit y assessment.
The causalit y assessm ent is one of the cri teria used when determining regulatory  
reporting requirements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by the sponsor 
or desi gnee to elucidate the nature and/or causalit y of the AE or SAE as fully as 
possible. This may include addit ional laboratory  tests or invest igations, 
histopathological examinat ions, or consultation with other healt h care professio nals.
New or updated informat ion will be recorded in the originally co mpleted eCRF.
The invest igator will submi t any  updated SAE data to the sponsor or designee within 
24 hours of receipt of the information.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
5610.3.4. Reporting of SAEs
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to the medical mo nitor or the SAE coordinator .
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
The investigator or site must alert the Lilly CRP/CP, or i ts desi gnee, of  any SAE as 
soon as practically possible.
Addit ionally , the invest igator or site must alert Lilly Global Pat ient Safet y, or its 
designee, of any SAE within 24 hours of investigator awareness of the event via a 
sponsor -approved me thod. If alerts are issued via telephone, they  are to be immediately 
followed wi th official  notificat ion on study -specific SAE forms. This 24- hour 
notification requirement refers to the init ial SAE informat ion and all fo llow
-up SAE 
inform ation.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
5710.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential
A wo man is considered fertile fo llowing menarche and unt il beco ming postmenopausal unless 
perm anent ly sterile (see below).
If fertilit y is uncle ar (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, addi tional eval uation shoul d be considered.
Women in the fo llowing categori es are not considered women of childbearing poten tial
1.Prem enarchal
2.Prem enopausal  female wi th 1 of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
Docum ented tubal  ligation
For individuals wit h perm anent infert ility due to an alternate medical cause other than the 
above (e .g., Müllerian agenesis, androgen insensit ivity), invest igator discret ion shoul d be 
applied to determining study  entry .
NOTE : Documentation can come from the site personnel’s :review of the participant’s 
medical records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female is defined as women wit h:
12 m onths of amenorrhea for women >55, with no need for follicle -stimulat ing hormone
12 m onths of amenorrhea fo r wom en >40 y ears old wi th follicle -stimulat ing horm one
≥40 m IU/mL and no other medical condit ion such as anorexia nervosa and not taking 
medicat ions during the amenorrhea (e.g. ,oral contraceptives, hormones, gonadotropin 
releasing hormone, ant i-estrogens , select ive estrogen receptor modulators, or 
chemotherapy that induced amenorrhea )
Contraception Guidance:
Contraceptive use by men or women should be consistent with local regulat ions regarding the 
methods of contraception for those participat ing in clini cal studies.
Male parti cipants:
are not required to adhere to con tracepti ve requi rements
Female participants:
Female participants of childbearing potential who are abst inent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a same sex relat ionship (as part of 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
58their pref erred and usual lifestyle) must agree to either remain abst inent or stay in a same 
sex rel ationship wit hout sexual relat ionships with males. Periodic abst inence (e.g., 
calendar, ovul ation, symptothermal, post -ovulation methods), declarat ion of abst inence 
just for the duration of a study , and wi thdrawal  are not acceptabl e method s of 
contraception.
Female participants of childbearing potential, who are not abstinent as described above, 
must agree to use a highly effect ive method of contraception (that is, one with less than 
1% failure rate) such as combinat ion or oral  contraceptiv es, implanted/injected 
contraceptives, intrauterine devices, or sterile partner until 30 days after the last dose of 
study  medicat ion. 
o Female participants not of childbearing potential are not required to use 
contraception. This includes females who are:
Infert ile due to surgical sterilization (hysterectomy, bilateral 
oophorectomy , bilateral  salpingectomy , or tubal  ligation) or congenital 
anomaly(for exam ple, Müllerian agenesis )
Postmenopausal , as defined above.
Collection of Pregnancy Information
Male pa rticipants wi th partners who become pregnant
●The invest igator will attempt to collect pregnancy informat ion on any male 
participant’s female partner who beco mes pregnant while the male participant is 
in this study . This applies only  to m ale parti cipants who receive study 
intervent ion.
●After obtaining the necessary  signed informed consent from the pregnant female 
partner direct ly, the invest igator will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the 
partner’s pregnancy. The female partner will also be fo llowed to determine the 
outcom e of the pregnancy . Informati on on the status of the mother and child will 
be forwarded to the sponsor. Generally, the fo llow-up will be no longer than 6 to 
8weeks following the estimated delivery date. Any terminat ion of the pregnancy 
will be reported including fetal status (presence or absence of ano malies) and
indicat ion for the procedure. 
Female participants who become pregnant
●The invest igator will collect pregnancy information on any female participant 
who beco mes pregnant while part icipating in this study . The init ial information 
will be recorded on the appropriate form and submitted to the sponsor within 
24hours of learning of a participant ’spregnancy . 
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
59●The parti cipant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect fo llow-up inform ation on the participant and the neonate,
and the information will be forwarded to the sponsor. Generally, fo llow-up will 
not be requi red for longer than 6 to 8 weeks bey ond the estimated delivery  date. 
Any terminat ion of pregnancy  will be reported, including fetal status (presence or 
absence of ano malies) or indicat ion for the procedure.
●While pregnancy  itself is not consid ered to be an AE or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  for medical  reasons will be 
reported as an AE or SAE. 
●A spontaneous abortion (occurring at <2 0weeks gestational age) or still birth 
(occurring at > 20weeks gestational age) is always considered to be an SAE and 
will be reported as such. 
●Any poststudy  pregnancy -related SAE considered reasonably  related to the study  
intervention by the investigator will be reported to the sponsor as described in 
Secti on8.3.4 . While the invest igator is not obligated to actively seek this 
inform ation in former study  parti cipants, he or she may learn o f an SAE thro ugh 
spontaneou s reporting.
●Any female part icipant who becomes pregnant while participat ing in the study  
will discont inue study  intervent ion.If the participant is discont inued from the 
study  interventi on, follow the standard di scont inuation process and c ontinue 
directly to the fo llow-up phase.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
6010.5. Appendix 5: Genetics
Use/Analysis of DNA
●Genet ic variat ion may impact a participant’s response to study  intervent ion, 
suscept ibilit y to, and severit y and progression o f disease. Variable response to 
study  interventi on may  be due to genetic determinants that impact drug 
absorpti on, di stribut ion, metabo lism, and excret ion; mechanism of act ion of the 
drug; di sease et iology; and/or mo lecular subt ype of the disease being treated. 
Therefore, where local regulat ions and IRB/IEC allow, a blood/saliva sample will 
be co llected for DNA analysis fro m consent ing parti cipants.
●DNA samples will be used for research related to selpercat inib or advanced or 
metastati c RET -mutant MTC/advanced or metastatic RET fusion -positive thy roid 
cancer/metastatic RET fusio n-positive NSCLC . They  may also be used to develop 
tests/assays including diagnost ic tests related to selpercatinib or advanced or 
metastati c RET -mutant MTC/advanced or metastatic RET fusion -positive thy roid 
cancer/metastatic RET fusio n-positive NSCLC .Genet ic research may consist of 
the analysis o f one or m ore candid ate genes or the analysis of genet ic markers 
throughout the geno me or analysis o f the ent ire geno me(as appropri ate).
●Addit ionalanalyses m ay be conducted if it is hypothesized that this may  help 
further understand the clinical data.
●The samples may  be analyzed as part of a mult i-study  assessment of genetic 
factors i nvolved in the response to selpercat inibor study  interventi ons of  this 
class to understand study  disease or related condit ions.
●The results of genet ic analyses may be report ed in the clinical study  report or in a 
separate study  summary.
● The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confident iality.
●The samples will be retained while research on selpercatinib or study  
intervent ions of this class or indicat ioncontinues but no l onger than 15years or 
other period as per local requirements.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
6110.6. Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments
Hepatic Evaluation Testing –Refer to protocol Hepatic Safety Section 8.2.5.1 for guidance on 
appropriate test selection.
For testing selected, analysis is required to be completed by the Lilly -designated central 
laboratory except for Microbiology.
Local testing may be performed in addition to central testing when required for immediate 
participant management.
Results will be reported if a validated test or calculation is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocytes (RBCs -Red Blood Cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -White Blood Cells) Alanine aminotransferase (ALT)
Differ ential: Aspartate aminotransferase (AST)
    Neutrophils, segmented Gamma -glutamyl transferase (GGT)
    Lymphocytes Creatine kinase (CK)
    Monocytes Other Chemistry   
    Basophils Acetaminophen
    Eosinophils Acetaminophen Protein Adducts
Platelets Alkaline Phosphatase Isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
CoagulationCopper
Ethyl Alcohol (EtOH)
Prothrombin Time, INR ( PT-INR) Haptoglobin
Serology Immunoglobulin IgA (Quantitative)
Hepatitis A Virus (HAV) Testing: Immunoglobulin IgG (Quantitative)
    HAV Total Antibody Immunoglobulin IgM (Quantitative)
    HAV IgM Antibody Phosphatidylethanol (PEth)
Hepatis B Virus (HBV) Testing : Urine Chemistry
    Hepatitis B surface antigen (HBsAg) Drug Screen
    Hepatitis B surface antibody (Anti -HBs) Ethyl glucuronide (EtG)
    Hepatitis B core total antibody (Anti -HBc) Other Serology
    Hepatitis B core IgM antibody Anti-nuclear antibody (ANA)
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
62    Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA)a
    HBV DNAdAnti-actin antibody b
Hepatis C Virus (HCV) Testing: Epstein -Barr Virus (EBV) Testing:
    HCV antibody     EBV antibody
    HCV RNAd    EBV DNAd
Hepatitis D Virus (HDV) Testing: Cytomegalovirus (CMV) Testing:
    HDV antibody     CMV antibody
Hepatitis E Virus (HEV) Testing:     CMV DNAd
    HEV IgG antibody Herpes Simplex Virus (HSV) Testing:
    HEV IgM antibody     HSV (Type 1 and 2) antibody
    HEV RNAd    HSV (Type 1 and 2) DNAd
Microbiologyc Liver Kidney Microsomal Type 1 (LKM -1) 
Antibody
Culture:
    Blood
    Urine
a This is not required if anti-actin antibody is tested.
b This is not required if ASMA is tested.
c  Assayed by investigator -designated local laboratory ONLY; no Central Testing available.
d Reflex/confirmation dependent on regulatory requirements and/or testing availability.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
63Evaluation of participants with treatment -emergent abnormal hepatic biochemical tests 
during a clinical trial *
Test/Procedure:  Rationale Action
Close Hepatic Monitoring
Clinical Chemistry:
    Total bilirubin
    Direct bilirubin
    Alkaline phosphatase (ALP)
    Alanine aminotransferase (ALT)
    Aspartate aminotransferase (AST)b
    Gamma -glutamyl transferase (GGT)
    Creatine kinase (CK)All:  Routine follow -up
CK: Muscle injury /rhabdomyolysisUtilize a Hepatic 
Monitoring central lab 
collection kit and select 
Clinical Chemistry 
Hematology
   Hemoglobin
   Hematocrit
   Erythrocy tes (RBCs –Red Blood 
Cells)
   Leukocytes (WBCs –White Blood 
Cells)
   Differential:
     Neutrophils, segmented
     Lymphocytes
     Monocytes
     Basophils
     Eosinophils
   Platelets
   Cell Morphology (RBCs and WBCs)Infection Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hematology
Medical history:a, h
    Symptoms
    Co-existing medical conditions
    Concomitant medications
    Dietary and nutritional supplements
    Exercise (excessive)
    Muscle Injury
    Alcohol consumption
    Illicit substancesUsed to evaluate/rule out:
   Systemic infection or sepsis
   Ischemic or congestive hepatic injury
   Gallstone disease
   Alcoholic liver disease
   Muscle injury/rhabdomyolysis
   Acetaminophen toxicity
   Drug Induced Liver Injury ( DILI )due 
to another drug, herbal or dietary 
substancesIf findings a re clinically  
significant, report as an 
adverse event.
Hepatitis A Virus (HAV) Testing:
    HAV Total Antibody
    HAV IgM AntibodyUsed to evaluate/rule out:  Acute HAV 
infectionUtilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hepatit isA
Hepatis B Virus (HBV) Testing:
    Hepatitis B surface antigen (HBsAg)
    Hepatitis B surface antibody 
(Anti-HBs) 
    Hepatitis B core total antibody 
(Anti-HBc)
    Hepatitis B core IgM antibody
    Hepatitis B core IgG antibody 
    HBV DNAUsed to evaluate/rule out:  Acute or 
exacerbation of chronic HBV infection. Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hepatitis B
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
64Hepatis C Virus (HCV) testing:c, d
    HCV antibody
    HCV RNAUsed to evaluate/rule out:  Acute or 
exacerbation of chronic HCV infection. Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hepatitis C
Hepatitis E Virus (HEV) Testing: e
    HEV IgG antibody
    HEV IgM antibody
    HEV RN AUsed to ev aluate/rule out:  Acute HEV 
infection.Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
Hepatitis E
Anti- nuclear antibody (ANA)
Anti-smooth muscle antibody (ASMA)
Anti- actin antibody
Immunoglobulin IgA
Immunoglobulin IgG
Immunoglobulin IgMUsed to evaluate/rule out:  Autoimmune 
hepatitisUtilize a Hepatic 
Monitoring central lab 
collection kit and select 
only the specific test/s 
required.  
Hepatobiliary imaging:a, h
    Ultrasonography
    Computed tomography scan
    Magnetic resonanc e imaging
    Magnetic resonance 
cholangiopancreatography (MRC P)g
Endoscopic retrograde 
cholangiopancreatography (ERCP)gUsed to evaluate/rule out:  
    Biliary obstruction
    Pancreatitis
    Gallstones
    Portal -vein/ hepatic vein thrombosis 
    Hepatic metastasisPerformed locally.
If findings are clinically 
significant, report as an 
adverse event.
Comprehensive Hepatic Monitoring
Coagulation:
Prothrombin Time, INR (PT -INR)Used to evaluate/rule out:
Suspected liver failure, for patients with 
elevated Total BilirubinUtilize a Hepatic 
Monitoring central lab 
collection kit
Epstein- Barr Virus (EBV) Testing:
    EBV antibody
    EBV DNA
Cytomegalovirus (CMV) Testing:
    CMV antibody
    CMV DNA
Herpes Simplex Virus (HSV) 
Testing:
    HSV (Type 1 and 2) antibody
    HSV (Type 1 and 2) DNAUsed to evaluate/rule out:
EBV or 
Hepatic injury due to CMV, or
HSV infection.Utilize a Hepatic 
Monitoring central lab 
collection kit and select 
only the specific test/s 
needed.
Liver biopsy fUsed to evaluate/rule out:
Autoimmune hepatitis (AIH)If findings are clinically 
significant, report as an 
adverse event.
Additional Hepatic Monitoring Tests
Alkaline Phosphatase Isoenzymes Used to evaluate/differentiate:  Elevated 
Alkaline Phosphatase origination from
bone or liverUtilize a Hepatic 
Monitoring central lab 
collection kit
Liver Kidney Microsomal Type 1 
(LMK-1) AntibodyUsed to evaluate:  Autoimmune 
hepatitis Utilize a Hepatic 
Monitoring central lab 
collection kit
Urine Chemistry:
   Ethyl glucuronide (EtG) i
Other Chemistry:
   Phosphatidylethanol (PEth)jUsed to evaluate:  Alcoholic liver 
disease  Utilize a Hepatic 
Monitoring central lab 
collection kit
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
65Other Chemistry:
   Acetaminophen
   Acetaminophen Protein AdductsUsed to evaluate:  Acetaminophen 
toxicity Utilize a Hepatic 
Monitoring central lab 
collection kit
Ethyl Alcohol (EtOH) Used to evaluate recent alcohol 
consumptionUtilize a Hepatic 
Monitoring central lab 
collection kit
Haptoglobin Used to evaluate a diagnosis of 
hemoly sisUtilize a Hepatic 
Monitoring central lab 
collection kit
Cardiology consulta
Electrocardiogram
Echocardiogram
Vital Signs:
    Blood pressure
    PulseUsed to evaluate:  Ischemic or 
congestive hepatic injuryPerformed locally.
If findings are clinically 
significant, report as an 
adverse event.
Urine Chemistry:
   Drug screenUsed to evaluate:  Hepatotoxicity due to 
cocaine, opiates and other illicit 
substances Utilize a Hepatic 
Monitoring central lab 
collection kit
Hepatitis D Virus (HDV) Testing:
    HDV antibodyUsed to evaluate/rule out:  Acute HDV 
infection.Utilize a Hepatic 
Monitoring central lab 
collection kit and only 
select required test needed.
Microbiology:  
Cultures:
    Blood
    UrineUsed to evaluate/rule out:  
Sepsis or systemic infectionPerform locally.
If findings are clinically 
significant, report as an 
adverse event.
Slit lamp eye examination (Kayser -
Fleisher rings)
Genetic evaluationUsed to evaluate/rule out:  
Wilson’s disease Perform locally. 
If findings are clinically 
significant, report as an 
adverse event.
Other Chemistry:
    Ceruloplasmin
    CopperUsed to evaluate/rule out:  
Wilson’s disease Utilize a Hepatic 
Monitoring central lab 
collection kit
*This tool is to be used by the investigative site for reference during the evaluation of a participant who met hepatic 
monitoring criteria based on laboratory results and clinical judgment for a suspected liver injury during protocol 
participation. 
aExtent and type of work -up may  vary  by participant’s history, severity of liver injury, underlying disease, and 
geography.
bSerum AST typically (although not always) is higher than ALT 
cIf anti -HCV is positive, HCV RNA is required to confirm HCV infect ion  
dAcute hepatitis C may be anti -HCV negative but HCV RNA positive
eIf anti -HEV IgM is positive, consider confirmation with HEV RNA by nested polymerase chain reaction
fA liver biopsy is needed to confirm a diagnosis of AIH
gIf cholestatic injury ,MRCP or ERCP may be recommended 
hBased on medical history and clinical judgment 
iAlcohol consumption in past 3 to 5 days
jAlcohol consumption in past 3 weeks
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
6610.7. Appendix 7: Abbreviations
Term Definition
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC(0 -∞) area under the concentration versus time curve from the time of dosing to infinity
CFR Code of Federal Regulations
CI confidence interval
Cmax maximum observed plasma concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performan ce of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CP clinical pharmacologist
CRF case report form
CRP clinical research physician: Individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CRU clinical research unit
CV coefficient of variation
DDI drug-dr ug interaction
ECG electrocardiogram
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
67FDA Food and Drug Administration
GCP good clinical practice
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by means of a written, signed and dated informed consent form .
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated o r packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRB Institutio nal Review Board
MTC medullary thyroid cance r
NSCLC non-small cell lung cancer
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
P-gp P-glycoprotein
PK pharmacokinetics
QTc corrected QT interval
QTcF QT interval correct for heart rate using Fridericia’s formula
RNA ribonucleic acid
SAE serious adverse event
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SoA Schedule of Activities
t1/2 terminal half -life
TBL total bilirubin
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
68tmax time to maximum observed plasma concentration
ULN upper limit of normal
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
6910.8. Appendix 8: Protocol Amendment History
Not applicable.
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
7010.9. Appendix 9: Protocol Amendment History
The Prot ocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment (a): 03 March 2021
This amendment is considered to be nonsubstant ialbased on the criteria set forth in Art icle 
10(a) of Direct ive 2001/20/EC of the European Parliament and the Council o f the European 
Unio n.
Overall Rationale for the Amendment
To include cla rificationregarding how the percentage of the standardized meal to be 
consumed by each participant will be calculated.
Section # and 
NameDescription of Change Brief Rationale
5 Study  Populati on Clinical laboratory  assessments 
and vital signs m ay be repeated at 
the discret ion of the invest igator 
in order to confirm eligibilit yper request from the PI
5.1 Incl usion CriteriaBilateral salpingectomy added to 
inclusio n #6 for consistency across the 
protocol
5.2 Excl usion CriteriaECG exclusio n now applicable at 
screening only instead of during 
‘baseline period’for clarity
5.3.1 Meals and 
Dietary  Restri ctionsText am ended to outline:
that components of the 
standardized meal will be 
weighed and docum ented 
in grams both pre -and 
post-meal todetermine the 
percentage of the m eal 
consumed by the 
participant .
that participants will 
complete the m eal 30 
minutes prior to dosing.for clarity
8.2.3 
ElectrocardiogramsECGs will be interpreted by  the 
investigator –not a qualified 
physician or qualified designeefor clarity
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
7110.2 Appendix 2: 
Clinical Laboratory  
TestsParti al thrombopl astin time 
removed from  list of coagulat ion 
param etersvendor does no t perf orm PTT 
assay ;only aPTT
Table footnote added to statethat 
urinalysis will be performed by  
dipstickfor clarity
Appendix 4: 
Contraceptive 
Guidance and 
Collect ion of 
Pregnancy 
Inform ationTubal ligat ion added to the 
category  descript ion of women 
not of childbearing potentialfor consistency across the 
protocol
Bilateral salpingectomy added to 
the category  descripti on of  
wom en not requi red to use 
contraception for consistency across the 
protocol
CONFIDENTIAL Protocol  J2G-MC-JZJV (a)
7211. References
Boehringer Ingelheim. Pradaxa® (dabiga tran etexilate) prescribing informat ion. July 2020 ; 
Accessed at https://docs.boehringer -
ingelheim.com/Prescribing%20Informat ion/PIs/Pradaxa/Pradaxa.pdf on 10 March 2020.
FDA Clinical DDI Draft Guidance : In Vi tro Drug Interacti on Studi es –Cytochrom e P450 
Enzyme -and Transporter -Medi ated Drug Interactions Guidance for Industry , 2020. Accessed 
at https://www.fda.gov/regulatory -informat ion/search -fda-guidance -docum ents/vi tro-drug-
interact ion-studi es-cytochrom e-p450- enzyme -and-transporter -mediated- drug-interacti ons on 
15 July  2020 .
Härtter S, Sennewald R, Nehmiz G, Reilly P .  Oral bioavailabilit y ofdabigatran etexilate 
(Pradaxa(®)) after co -medication wi th verapamil in healt hy subjects.   Br J Clin Pharmacol. 
2013 Apr; 75(4):1053 -62.
International Transporter Consortium, Giaco mini KM, Huang SM, et al. Membrane transporters 
in drug development. Nat R ev Drug Discov . 2010;9(3):215 -236.
Levey , Andrew S., Lesl ey A. Stevens, Christopher H. Schmid, Yaping (Lucy ) Zhang, Alejandro 
F. Castro, Harold I. Feldman, John W. Kusek, et al. 2009. “A New Equation to Estimate 
Glomerular Fil tration Rate.” Annals of Internal Medi cine 150 (9): 604.
Loxo Oncology , Inc. Selpercat inib (LOXO -292) –Invest igator’s Brochure (Versi on 7.0 )
01June 2020.
Stangi er J. Clinical pharmacokinet ics and pharmacodynamics of the oral direct thrombin
inhibitor dabigatran etexilate. Clin Pharmacokinet . 2008;47(5):285 -
295.
Stangi erJ, Rathgen K,Stähle H,et al. The pharmacokinet ics, pharmacodynamics and tolerabilit y 
of dabigatran etexilate, a new oral direct thrombin inhibitor, in healt hy male subjects . Br J Clin 
Pharmacol .2007 Sep; 64(3):292 -303.
L e o  D o c u m e n t  I D  =  3 4 7 8 5 e 4 9 - 6 7 a 1 - 4 6 f 8 - 8 e a a - b 1 8 b b d 6 5 9 f 3 3 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 4 - M a r - 2 0 2 1  1 7 : 2 6 : 4 9  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 5 - M a r - 2 0 2 1  1 4 : 3 2 : 3 9  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 